[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 63 of about 63
1. Mortazavi H, Abedini R, Sadri F, Soori T, Vasheghani-Farahani A: Crusted scabies in a patient with brain astrocytoma: report of a case. Int J Infect Dis; 2010 Jun;14(6):e526-7
MedlinePlus Health Information. consumer health - Scabies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crusted scabies in a patient with brain astrocytoma: report of a case.
  • He suffered from a brain tumor (astrocytoma) and was immunosuppressed because he was receiving systemic steroids and chemo-radiation therapy.
  • He also had psychomotor retardation and behavior changes due to the pressure effect of his brain tumor.
  • The diagnosis of crusted scabies was established based on direct positive skin smears from the lesions.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Sarcoptes scabiei. Scabies / diagnosis
  • [MeSH-minor] Adult. Animals. Diagnosis, Differential. Fatal Outcome. Humans. Immunocompromised Host. Male. Pruritus / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19700360.001).
  • [ISSN] 1878-3511
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


2. Allerstorfer S, Sonvilla G, Fischer H, Spiegl-Kreinecker S, Gauglhofer C, Setinek U, Czech T, Marosi C, Buchroithner J, Pichler J, Silye R, Mohr T, Holzmann K, Grasl-Kraupp B, Marian B, Grusch M, Fischer J, Micksche M, Berger W: FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene; 2008 Jul 10;27(30):4180-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report simultaneous overexpression of FGF5 and its predominant high-affinity receptor (FGFR1 IIIc) in astrocytic brain tumour specimens (N=49) and cell cultures (N=49).
  • Moreover, tumour cell migration was distinctly stimulated by rFGF5 but attenuated by FGF5 siRNA.
  • In summary, we demonstrate for the first time that FGF5 contributes to the malignant progression of human astrocytic brain tumours by both autocrine and paracrine effects.
  • [MeSH-major] Autocrine Communication / physiology. Brain Neoplasms / genetics. Fibroblast Growth Factor 5 / physiology. Glioblastoma / genetics. Oncogenes. Paracrine Communication / physiology
  • [MeSH-minor] Cell Death / drug effects. Cell Movement / drug effects. Cell Proliferation / drug effects. Culture Media, Conditioned / pharmacology. Disease Progression. Genes, Dominant / physiology. Humans. Mutant Proteins / genetics. Mutant Proteins / physiology. Neovascularization, Pathologic / chemically induced. Neovascularization, Pathologic / genetics. Recombinant Proteins / pharmacology. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res Mol Brain Res. 1996 May;38(1):161-5 [8737680.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Vet Pathol. 1997 May;34(3):171-9 [9163872.001]
  • [Cites] Oncogene. 1997 Sep 18;15(12):1417-24 [9333017.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;59:135-76 [9427842.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):352-61 [9443417.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):189-95; discussion 196 [9457270.001]
  • [Cites] Biochem Cell Biol. 1997;75(6):669-85 [9599656.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jul;286(1):569-77 [9655904.001]
  • [Cites] Neurosurgery. 1998 Aug;43(2):337-46 [9696088.001]
  • [Cites] J Biol Chem. 1998 Oct 30;273(44):29262-71 [9786939.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5285-90 [9850049.001]
  • [Cites] J Invest Dermatol. 1998 Dec;111(6):963-72 [9856803.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):415-23 [10495436.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jun;131(6):355-63 [15856298.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49 [15863030.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86 [15863033.001]
  • [Cites] Growth Factors. 2005 Jun;23(2):87-95 [16019430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6 [16046538.001]
  • [Cites] Biochem Pharmacol. 2006 Feb 14;71(4):426-40 [16343446.001]
  • [Cites] J Cell Sci. 2006 Feb 1;119(Pt 3):459-69 [16418217.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3584-92 [16585183.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] Mol Cancer Res. 2006 Dec;4(12):927-34 [17189383.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):960-9 [17342095.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4055-63 [17720881.001]
  • [Cites] J Neurosci. 2003 Jul 23;23(16):6404-12 [12878680.001]
  • [Cites] Cell Tissue Res. 2003 Aug;313(2):139-57 [12845521.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3487-95 [3211147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(20):8022-6 [1700424.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):1840-5 [2005884.001]
  • [Cites] Development. 1991 Jun;112(2):397-406 [1794310.001]
  • [Cites] J Invest Dermatol. 2000 Mar;114(3):456-63 [10692103.001]
  • [Cites] Glia. 2000 May;30(3):231-41 [10756073.001]
  • [Cites] Nat Cell Biol. 2001 Jul;3(7):650-7 [11433297.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5511-6 [11454700.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):329-39 [11839785.001]
  • [Cites] Int J Pancreatol. 2001;29(2):85-92 [11876253.001]
  • [Cites] Neurol Res. 2002 Apr;24(3):244-8 [11958417.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):773-80 [12574212.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):209-14 [8381111.001]
  • [Cites] Neuron. 1993 Mar;10(3):369-77 [8461132.001]
  • [Cites] Brain Res. 1993 Mar 19;606(1):79-86 [8462006.001]
  • [Cites] Eur J Neurosci. 1994 Feb 1;6(2):244-52 [8167846.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2794-9 [8168112.001]
  • [Cites] Cell. 1994 Sep 23;78(6):1017-25 [7923352.001]
  • [Cites] J Neurooncol. 1994;18(3):207-16 [7964981.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):171-83 [9010219.001]
  • (PMID = 18362893.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 19920
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / FGF5 protein, human; 0 / Mutant Proteins; 0 / Recombinant Proteins; 129653-64-1 / Fibroblast Growth Factor 5
  • [Other-IDs] NLM/ PMC2879862; NLM/ UKMS30927
  •  go-up   go-down


3. Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, Agúndez JA, García-Martín E: Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol; 2010;10:71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma.
  • Aiming to identify genetic variations related to the risk of developing brain tumors, we investigated the putative association between common nonsynonymous PON1 polymorphisms and the risk of developing astrocytoma and meningioma.
  • METHODS: Seventy one consecutive patients with brain tumors (43 with astrocytoma grade II/III and 28 with meningioma) with ages ranging 21 to 76 years, and 220 healthy controls subjects were analyzed for the frequency of the nonsynonymous PON1 genotypes L55M rs854560 and Q192R rs662.
  • RESULTS: The frequencies of the PON1 genotypes and allelic variants of the polymorphisms PON1 L55M and PON1 Q192R did not differ significantly between patients with astrocytoma and meningioma and controls.
  • The minor allele frequencies were as follows: PON1 55L, 0.398, 0.328 and 0.286 for patients with astrocytoma, meningioma and control individuals, respectively; PON1 192R, 0.341, 0.362 and 0.302 for patients with astrocytoma, meningioma and control individuals, respectively.
  • Haplotype association analyses did not identify any significant association with the risk of developing astrocytoma or meningioma.
  • CONCLUSIONS: Common nonsynonymous PON1 polymorphisms are not related with the risk of developing astrocytoma and meningioma.
  • [MeSH-major] Aryldialkylphosphatase / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1998 Sep;34(3):252-60 [9698994.001]
  • [Cites] Atherosclerosis. 1998 Aug;139(2):341-9 [9712341.001]
  • [Cites] Biochem Pharmacol. 1998 Sep 1;56(5):547-51 [9783722.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):116-25 [15386358.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):546-51 [15866761.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):909-13 [16002382.001]
  • [Cites] Liver Int. 2005 Oct;25(5):935-9 [16162149.001]
  • [Cites] Toxicology. 2005 Nov 15;215(3):182-90 [16102884.001]
  • [Cites] Occup Environ Med. 2005 Nov;62(11):786-92 [16234405.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):615-20 [16489678.001]
  • [Cites] Acta Neurol Scand. 2006 May;113(5):322-6 [16629768.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1513-6 [16685388.001]
  • [Cites] Pharmacogenomics. 2006 Jul;7(5):711-8 [16886896.001]
  • [Cites] Cell Biochem Funct. 2006 Sep-Oct;24(5):455-60 [16142697.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • [Cites] Drug Metab Dispos. 2007 Feb;35(2):315-20 [17132760.001]
  • [Cites] Occup Environ Med. 2007 Aug;64(8):509-14 [17537748.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jan;18(1):37-43 [18216720.001]
  • [Cites] Am J Epidemiol. 2008 Apr 15;167(8):976-85 [18299277.001]
  • [Cites] Clin Chem. 2008 Aug;54(8):1390-4 [18664443.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):520-31 [18680472.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):709-15 [18682580.001]
  • [Cites] Psychiatr Genet. 2008 Dec;18(6):289-94 [19018234.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Apr 15;236(2):142-53 [19371602.001]
  • [Cites] Cell Biochem Funct. 2009 Dec;27(8):558-67 [19902425.001]
  • [Cites] Environ Health Perspect. 2010 Jan;118(1):144-9 [20056567.001]
  • [Cites] Adv Exp Med Biol. 2010;660:47-60 [20221870.001]
  • [Cites] Eur J Neurol. 2010 Jun 1;17(6):879-81 [20050883.001]
  • [Cites] Chem Biol Interact. 2010 Sep 6;187(1-3):355-61 [20338154.001]
  • [Cites] Neuromolecular Med. 2010 Sep;12(3):217-23 [19826962.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):15-23 [10099836.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):767-79 [11191881.001]
  • [Cites] J Lipid Res. 2001 Apr;42(4):528-35 [11290824.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 15;173(1):1-6 [11350209.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):909-13 [11673119.001]
  • [Cites] Ann Diagn Pathol. 2002 Feb;6(1):44-8 [11842378.001]
  • [Cites] Curr Opin Lipidol. 2002 Aug;13(4):357-62 [12151850.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):214-27 [12210690.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):139-50 [12749719.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):182-4 [12820764.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] J Mol Med (Berl). 2003 Dec;81(12):766-79 [14551701.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Am J Ind Med. 2004 May;45(5):395-407 [15095422.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Arch Pathol Lab Med. 1979 Dec;103(13):676-9 [583126.001]
  • [Cites] J Neurol. 1982;227(3):165-9 [6181224.001]
  • [Cites] Indian J Cancer. 1983 Mar;20(1A):86-8 [6873998.001]
  • [Cites] Am J Epidemiol. 1988 Oct;128(4):778-85 [3421243.001]
  • [Cites] Neurologia. 1988 Mar-Apr;3(2):68-70 [2856211.001]
  • [Cites] J Neurosci Nurs. 1992 Oct;24(5):260-4 [1328422.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):598-608 [7916578.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):73-6 [8098250.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):599-604; discussion 604-5 [7753363.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4237-9 [7671227.001]
  • [Cites] J Neurosurg Sci. 1995 Mar;39(1):27-35 [8568553.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Curr Opin Lipidol. 1996 Apr;7(2):69-76 [8743898.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):334-6 [8896566.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):284-7 [9685159.001]
  • (PMID = 20723250.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human
  • [Other-IDs] NLM/ PMC2936881
  •  go-up   go-down


Advertisement
4. Kostic A, Mihailovic D, Veselinovic S, Tasic D, Stefanovic I, Novak V, Stojanovic N, Veselinovic D, Pavlovic S: Tumor size and karyometric variables in brain astrocytoma. J BUON; 2009 Jul-Sep;14(3):473-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor size and karyometric variables in brain astrocytoma.
  • PURPOSE: To show any possible correlation of some karyometric variables with tumor size in patients with brain astrocytoma, in order to confirm karyometry as an objective histological method.
  • PATIENTS AND METHODS: The study included 63 patients of different ages and both genders with brain astrocytoma histologically confirmed on the surgically removed material.
  • In all patients maximal tumor excision was done, and all were postoperatively treated according to different therapeutic protocols.
  • Tumor size (preoperative CT scan) was correlated with the duration of survival and the values of some karyometric tumor variables: area, density, maximal axis, mean axis, minimal axis, circumference, roundness, integrated optical density (IOD) and number of nuclei.
  • RESULTS: Patients were separated into 3 groups according to the average tumor diameter.
  • Seven out of 9 examined karyometric variables were significantly related (p<0.05) to the tumor size: area, maximal axis, mean axis, minimal axis, circumference, roundness and IOD.
  • The results of our morphometric analysis of the tumor cell nuclei, after correlation with CT findings, revealed that nuclear pleomorphism and larger nuclear size are associated with larger brain astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Nucleus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810141.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


5. Li M, Jia ZZ, Gu HM, Zhou XJ, Tang LM: [Application of apparent diffusion coefficient and fractional anisotropy in identification of tumor component and grading of brain astrocytoma]. Zhonghua Yi Xue Za Zhi; 2008 Dec 23;88(47):3352-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of apparent diffusion coefficient and fractional anisotropy in identification of tumor component and grading of brain astrocytoma].
  • OBJECTIVE: To evaluate the value of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in identification of tumor element and grading of brain astrocytoma.
  • METHODS: Thirty-three patients with histologically confirmed astrocytoma underwent diffusion weighted imaging (DWI), diffusion tensor imaging (DTI), and conventional MRI before operation.
  • The values of ADC and FA of different regions in the same tumor and of astrocytoma of different grades were measured and compared.
  • RESULTS: The ADC values of the tumor parenchyma, necrotic region, peritumoral edema region were (1.28 +/- 0.44), (1.97 +/- 0.53), and (1.74 +/- 0.47) respectively, all significantly higher than that of the corresponding normal brain tissues [(0.80 +/- 0.18), P = 0.009, P = 0.000, P = 0.000] with significantly differences between the tumor parenchyma and necrotic region and peritumoral edema region (both P < 0.05), however, there was not significant difference between the necrotic region and peritumoral edema region.
  • The FA values of the tumor parenchyma, necrotic region, and peritumoral edema region were (0.18 +/- 0.07), (0.14 +/- 0.05), and (0.16 +/- 0.05) respectively, all significantly higher than that of the corresponding normal brain tissues [(0.58 +/- 0.10), all P = 0.000], without significant differences among the former 3 groups.
  • There were no significant differences in the ADC and FA values among the tumors at different grades, however, there was a tendency of ADC to decrease and of FA to increase along the increase of grade of tumor, although not significantly.
  • CONCLUSION: ADC value plays an important part in distinguishing tumor components and determining tumor boundary, and plays a certain role in judging the grade of astrocytomas.
  • FA value is vital to determine the tumor boundary, and has certain value in differentiating high-grade from low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Anisotropy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19257968.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


6. Santel T, Pflug G, Hemdan NY, Schäfer A, Hollenbach M, Buchold M, Hintersdorf A, Lindner I, Otto A, Bigl M, Oerlecke I, Hutschenreuther A, Sack U, Huse K, Groth M, Birkemeyer C, Schellenberger W, Gebhardt R, Platzer M, Weiss T, Vijayalakshmi MA, Krüger M, Birkenmeier G: Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PLoS One; 2008;3(10):e3508
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity.
  • METHODOLOGY/PRINCIPAL FINDINGS: Cultures of whole blood cells and tumor cell lines (PC-3, JIM-1, MDA-MD 231 and 1321N1) were set up to investigate the effect of selected polyphenols, including curcumin, on the LPS-induced cytokine production (cytometric bead-based array), cell proliferation (WST-1 assay), cytosolic Glo1 and Glo2 enzymatic activity, apoptosis/necrosis (annexin V-FITC/propidium iodide staining; flow cytometric analysis) as well as GSH and ATP content.
  • Moreover, whereas curcumin was found to hamper the growth of breast cancer (JIMT-1, MDA-MB-231), prostate cancer PC-3 and brain astrocytoma 1321N1 cells, no effect on growth or vitality of human primary hepatocytes was elucidated.
  • Curcumin decreased D-lactate release by tumor cells, another clue for inhibition of intracellular Glo1.
  • This may account for curcumin's potency as an anti-inflammatory and anti-tumor agent.

  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol Interact. 2000 Aug 15;128(1):19-38 [10996298.001]
  • [Cites] J Cell Biochem. 2007 May 15;101(2):307-20 [17171638.001]
  • [Cites] FEBS Lett. 2001 Apr 20;495(1-2):131-6 [11322961.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2513-8 [11489834.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45770-5 [12226095.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1053-62 [12393461.001]
  • [Cites] J Hepatol. 2003 Apr;38(4):476-82 [12663240.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):363-98 [12680238.001]
  • [Cites] Crit Rev Food Sci Nutr. 2004;44(2):97-111 [15116757.001]
  • [Cites] Biochem Pharmacol. 2004 Oct 1;68(7):1433-42 [15345333.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Anal Biochem. 1980 Feb;102(1):39-46 [7356162.001]
  • [Cites] Methods Enzymol. 1982;90 Pt E:535-41 [7154966.001]
  • [Cites] Biochim Biophys Acta. 1985 May 20;829(1):109-18 [3888271.001]
  • [Cites] Biochim Biophys Acta. 1985 May 20;829(1):119-26 [3888272.001]
  • [Cites] Mech Ageing Dev. 1989 Apr;48(1):63-71 [2725076.001]
  • [Cites] Neurobiol Aging. 2007 Jul;28(7):1044-50 [16781798.001]
  • [Cites] Int J Oncol. 2007 Jul;31(1):161-8 [17549417.001]
  • [Cites] Adv Exp Med Biol. 2007;595:105-25 [17569207.001]
  • [Cites] Adv Exp Med Biol. 2007;595:227-43 [17569214.001]
  • [Cites] Adv Exp Med Biol. 2007;595:321-41 [17569218.001]
  • [Cites] Biochem Pharmacol. 2007 Aug 15;74(4):579-89 [17617381.001]
  • [Cites] Free Radic Biol Med. 2007 Aug 15;43(4):568-80 [17640567.001]
  • [Cites] J Neurochem. 2007 Aug;102(4):1095-104 [17472706.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):724-8 [18089954.001]
  • [Cites] Biochem J. 2008 Feb 15;410(1):147-55 [17953519.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2008 Feb;56(2):162-7 [18239300.001]
  • [Cites] Biochem Pharmacol. 2008 Feb 15;75(4):787-809 [17900536.001]
  • [Cites] Aging Cell. 2008 Mar;7(2):260-9 [18221415.001]
  • [Cites] Bioorg Med Chem. 2008 Apr 1;16(7):3969-75 [18258440.001]
  • [Cites] World J Gastroenterol. 2008 Apr 14;14(14):2174-8 [18407590.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jul;62(2):215-26 [17896107.001]
  • [Cites] Mol Nutr Food Res. 2008 Jun;52 Suppl 1:S103-27 [18496811.001]
  • [Cites] Biochem Pharmacol. 2008 Sep 1;76(5):631-44 [18625205.001]
  • [Cites] Biomed Pharmacother. 2008 Nov;62(9):630-6 [18325727.001]
  • [Cites] J Neurochem. 2008 Jun 1;105(6):2489-500 [18399961.001]
  • [Cites] J Agric Food Chem. 2001 Mar;49(3):1464-74 [11312881.001]
  • [Cites] J Clin Neuroophthalmol. 1991 Mar;11(1):58-61 [1827463.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):233-40 [1904465.001]
  • [Cites] Biochem Pharmacol. 1996 May 17;51(10):1365-72 [8787553.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5533-8 [9576917.001]
  • [Cites] Chem Biol Interact. 1998 Apr 24;111-112:263-75 [9679560.001]
  • [Cites] Indian J Gastroenterol. 1999 Jul-Sep;18(3):118-21 [10407566.001]
  • [Cites] Arch Biochem Biophys. 1959 May;82(1):70-7 [13650640.001]
  • [Cites] Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52 [15386533.001]
  • [Cites] Science. 1956 Aug 10;124(3215):269-70 [13351639.001]
  • [Cites] J Agric Food Chem. 2005 Feb 23;53(4):959-63 [15713005.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1042:372-8 [15965083.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1043:135-45 [16037232.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1842-53 [16087329.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36708-13 [16141205.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38720-8 [16172117.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:206-17 [16387689.001]
  • [Cites] J Nat Prod. 2006 Mar;69(3):351-5 [16562833.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1397-421 [16563357.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):11864-71 [16505483.001]
  • [Cites] Antimicrob Agents Chemother. 2006 May;50(5):1859-60 [16641461.001]
  • [Cites] Free Radic Biol Med. 2006 Jul 1;41(1):65-76 [16781454.001]
  • [Cites] Crit Care Med. 2006 Jul;34(7):1874-82 [16715036.001]
  • [Cites] Mol Cell Biochem. 2006 Oct;290(1-2):87-96 [16770527.001]
  • [Cites] J Am Chem Soc. 2007 Jan 31;129(4):873-80 [17243824.001]
  • [Cites] J Clin Immunol. 2007 Jan;27(1):19-35 [17211725.001]
  • [ErratumIn] PLoS One. 2011;6(7). doi:10.1371/annotation/0eb2b9f3-1006-4dcd-ad61-367310a2686a. Hutschenreuter, Antje [corrected to Hutschenreuther, Antje]
  • (PMID = 18946510.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Interleukin-1beta; 0 / Lipopolysaccharides; 0 / Phenols; 0 / Polyphenols; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 4.4.1.5 / Lactoylglutathione Lyase; IT942ZTH98 / Curcumin
  • [Other-IDs] NLM/ PMC2567432
  •  go-up   go-down


7. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, DePinho RA, Chin L: Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev; 2007 Jan 1;21(1):98-111
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma (GBM) is an astrocytic brain tumor characterized by an aggressive clinical course and intense resistance to all therapeutic modalities.
  • Enforced Bcl2L12 expression confers marked apoptosis resistance in primary cortical astrocytes, and, conversely, its RNA interference (RNAi)-mediated knockdown sensitizes human glioma cell lines toward apoptosis in vitro and impairs tumor growth with increased intratumoral apoptosis in vivo.
  • Thus, Bcl2L12 contributes to the classical tumor biological features of GBM such as intense apoptosis resistance and florid necrosis, and may provide a target for enhanced therapeutic responsiveness of this lethal cancer.

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1157-68 [11753564.001]
  • [Cites] Cell Death Differ. 2001 Apr;8(4):403-10 [11550092.001]
  • [Cites] Exp Hematol. 2002 Jun;30(6):503-12 [12063017.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):191-5 [12110890.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 [12182418.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] J Neurochem. 2003 Jan;84(2):273-81 [12558990.001]
  • [Cites] Thromb Haemost. 2003 Jun;89(6):1081-8 [12783122.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1030-9 [14583630.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):25-35 [14749124.001]
  • [Cites] Cell. 2004 Feb 20;116(4):527-40 [14980220.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2757-65 [15077139.001]
  • [Cites] J Neurooncol. 2004 May;67(3):273-80 [15164982.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27320-6 [15140875.001]
  • [Cites] Biol Chem. 2004 Sep;385(9):779-83 [15493871.001]
  • [Cites] J Cell Biol. 1980 Jun;85(3):890-902 [6248568.001]
  • [Cites] Int J Cancer. 1993 Nov 11;55(5):760-4 [8244572.001]
  • [Cites] Neuropathol Appl Neurobiol. 1993 Oct;19(5):436-42 [8278027.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):352-61 [8625245.001]
  • [Cites] J Virol. 1996 Aug;70(8):5701-5 [8764092.001]
  • [Cites] J Exp Med. 1997 Apr 21;185(8):1481-6 [9126928.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5724-9 [9576951.001]
  • [Cites] J Exp Med. 1998 Sep 21;188(6):1185-90 [9743536.001]
  • [Cites] J Cell Biol. 1999 Jan 25;144(2):281-92 [9922454.001]
  • [Cites] Methods. 1999 Apr;17(4):313-9 [10196102.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22532-8 [10428830.001]
  • [Cites] J Neurosci. 2004 Nov 3;24(44):9977-84 [15525783.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11059-66 [15653686.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):287-97 [15803136.001]
  • [Cites] Genes Dev. 2006 Jan 1;20(1):1-15 [16391229.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):261-70 [16395408.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):18-23 [16397209.001]
  • [Cites] Science. 2006 Feb 10;311(5762):847-51 [16469926.001]
  • [Cites] Mol Cell. 2006 Aug;23(4):523-33 [16916640.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):48-55 [16647810.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):763-8 [10567494.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1241-7 [11062535.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 23;281(2):322-7 [11181049.001]
  • [Cites] Bioessays. 2001 Feb;23(2):111-5 [11169582.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1162-70 [11221847.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2759-65 [11289159.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16059-63 [11274139.001]
  • [Cites] J Biochem. 2001 Jun;129(6):963-9 [11388913.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Genomics. 2001 Mar 1;72(2):217-21 [11401436.001]
  • [Cites] Cell Death Differ. 2001 Apr;8(4):335-44 [11550085.001]
  • [ErratumIn] Genes Dev. 2007 Feb 15;21(4):481
  • (PMID = 17210792.001).
  • [ISSN] 0890-9369
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA099041; United States / NCI NIH HHS / CA / P01 CA095616; United States / NINDS NIH HHS / NS / K08 NS042737; United States / NCI NIH HHS / CA / R01 CA57683; United States / NCI NIH HHS / CA / R01 CA057683; United States / NCI NIH HHS / CA / P01 CA95616; United States / NINDS NIH HHS / NS / K08NS42737
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosomes; 0 / BCL2L12 protein, human; 0 / Bcl2l2 protein, mouse; 0 / Immunoglobulin G; 0 / Muscle Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspase 9
  • [Other-IDs] NLM/ PMC1759904
  •  go-up   go-down


8. Karmakar S, Banik NL, Patel SJ, Ray SK: 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells. Neurosci Lett; 2007 Mar 30;415(3):242-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma is the most common astrocytic brain tumor in humans.
  • We used 5-aminolevulinic acid (5-ALA) as a photosensitizer for PDT to induce apoptosis in human malignant glioblastoma U87MG cells and to understand the underlying molecular mechanisms.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histochem J. 1981 Jul;13(4):681-92 [6975767.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Photochem Photobiol. 1992 Jan;55(1):145-57 [1603846.001]
  • [Cites] Science. 1996 Nov 1;274(5288):782-4 [8864118.001]
  • [Cites] Biochem J. 1996 Nov 1;319 ( Pt 3):683-90 [8920967.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2282-308 [9191516.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):96-9 [9422513.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22490-7 [9712874.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1680-3 [9733516.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):387, 389 [9989401.001]
  • [Cites] Arch Biochem Biophys. 2004 Dec 15;432(2):178-87 [15542056.001]
  • [Cites] Arch Biochem Biophys. 2005 Jan 15;433(2):435-46 [15581600.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):289-99 [15662970.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6447-54 [15590628.001]
  • [Cites] Glia. 2005 Apr 15;50(2):160-7 [15685605.001]
  • [Cites] Biochim Biophys Acta. 2005 Feb 11;1722(1):43-50 [15716135.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1551-60 [15742333.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):516-28 [15827324.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11051-60 [16322255.001]
  • [Cites] Neuroscience. 2006 May 12;139(2):577-95 [16504408.001]
  • [Cites] Neuroscience. 2006 Sep 1;141(3):1265-80 [16765523.001]
  • [Cites] Apoptosis. 2006 Sep;11(9):1629-41 [16820963.001]
  • [Cites] Neurosci Lett. 2006 Oct 16;407(1):53-8 [16949208.001]
  • [Cites] J Neurochem. 2000 Apr;74(4):1646-55 [10737623.001]
  • [Cites] J Neurosci. 2000 Apr 15;20(8):2825-34 [10751434.001]
  • [Cites] FEBS Lett. 2000 Sep 1;480(2-3):193-6 [11034327.001]
  • [Cites] Cell Death Differ. 2000 Oct;7(10):866-7 [11279531.001]
  • [Cites] J Photochem Photobiol B. 2003 Feb;69(2):71-85 [12633980.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12(7):791-801 [12651874.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14162-7 [12576481.001]
  • [Cites] J Photochem Photobiol B. 2004 Jan 23;73(1-2):67-78 [14732253.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2746-56 [15077138.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2785-96 [15077142.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Immunol. 1990 May 1;144(9):3326-33 [1691753.001]
  • (PMID = 17335970.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS057811-01A1; United States / NCI NIH HHS / CA / R01 CA091460-04; United States / NCI NIH HHS / CA / R01 CA091460; United States / NINDS NIH HHS / NS / R01 NS 57811; United States / NCI NIH HHS / CA / R01 CA 91460; United States / NINDS NIH HHS / NS / R01 NS057811
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Apoptosis Inducing Factor; 0 / Apoptosis Regulatory Proteins; 0 / BIRC3 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / NF-kappa B; 88755TAZ87 / Aminolevulinic Acid; EC 3.4.- / Peptide Hydrolases; EC 3.4.22.- / Calpain; EC 3.4.22.- / Caspases; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ NIHMS20981; NLM/ PMC2533742
  •  go-up   go-down


9. Kostic A, Mihailovic D, Veselinovic S, Tasic G, Radulovic D, Stefanovic I: Peritumoral edema and karyometric variables in astrocytoma of the brain. J BUON; 2007 Apr-Jun;12(2):239-43
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral edema and karyometric variables in astrocytoma of the brain.
  • PURPOSE: The aim of this study was to evaluate karyometry as a quantitative and objective histological method by showing correlation of some karyometric variables with the severity of peritumoral edema in patients with brain astrocytoma.
  • The patients were diagnosed with astrocytoma of the brain, histologically confirmed on the surgically removed material.
  • Maximal tumor excision was performed in all patients, who were postoperatively treated according to current oncologic therapeutic protocols.
  • The intensity of perifocal edema (preoperative CT scan) was correlated to the duration of survival and the values of 9 karyometric tumor variables: area, density, maximal axis, mean axis, circumference, roundness, integrated optical density and number of nuclei.
  • Correlation of karyometric variables with CT findings revealed that higher degrees of tumor cellularity and nuclear wrinkling with increased integrated optical density is associated with larger peritumoral edema.
  • [MeSH-major] Astrocytoma / pathology. Brain Edema / pathology. Brain Neoplasms / pathology

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600879.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Lu ZQ, Wang YM, Cao YY, Zhang QJ, Zhang XH, Li YH, Wang HS, Xie HL, Jiao BH, Zhang JH: [Correlations of polymorphisms in matrix metalloproteinase-3 and -7 promoters to susceptibility to brain astrocytoma]. Ai Zheng; 2007 May;26(5):463-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of polymorphisms in matrix metalloproteinase-3 and -7 promoters to susceptibility to brain astrocytoma].
  • BACKGROUND & OBJECTIVE: Matrix metalloproteinases (MMPs) are key enzymes involved in tumor development, invasion and metastasis.
  • The single nucleotide polymorphisms (SNPs) in the promoter regions of MMP genes may influence tumor development and progression via modulating mRNA transcription and protein expression.
  • This study was to explore the correlations of the promoter SNPs in MMP-3 and MMP-7 genes to susceptibility to brain astrocytoma.
  • METHODS: The genotype of MMP-3 -1171 5A/6A and MMP-7 -181A/G polymorphisms in 236 patients with brain astrocytoma and 366 healthy controls was detected by polymerase chain reaction-restrictive fragment length polymorphism (PCR-RFLP).
  • RESULTS: The allelotype and overall genotype distribution of MMP-3 SNP among the astrocytoma patients and healthy controls were similar (P>0.05).
  • Stratified by sex, age, and histological grade, the susceptibility to brain astrocytoma among the subjects with 5A/5A and 5A/6A genotypes and the subjects with 6A/6A genotype were similar(P>0.05).
  • The overall genotype distribution of MMP-7 SNP among the astrocytoma patients and healthy controls were significantly different (P = 0.001).
  • Compared with the A/A genotype, both the G/G and the A/G genotypes significantly increased the susceptibility to astrocytoma [sex-and age-adjusted odds ratio (OR) = 2.77 and 1.69, 95% confidence interval (CI)=1.27-6.02 and 1.01-2.84, respectively].
  • Stratification analysis showed that the G/G genotype significantly increased the susceptibility to astrocytoma in men (adjusted OR = 3.24, 95% CI = 1.12-9.41) and in the individuals younger than 45 years (adjusted OR = 3.16, 95% CI = 1.09-9.16).
  • When stratified by histological grade, the A/G genotype increased the susceptibility to grade II astrocytoma by about 2 folds (adjusted OR = 2.06, 95% CI = 1.05 - 4.05), while the G/G genotype increased the susceptibility to grade II-IV astrocytoma by about 3 folds.
  • CONCLUSION: MMP-7 -181A/G polymorphism may influence the susceptibility to astrocytoma, while MMP-3-1171 5A/6A polymorphism has no correlation to the susceptibility.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genetic Predisposition to Disease. Matrix Metalloproteinase 3 / genetics. Matrix Metalloproteinase 7 / genetics. Polymorphism, Single Nucleotide

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672933.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.4.24.17 / MMP3 protein, human; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


11. Lee WH, Jin JS, Tsai WC, Chen YT, Chang WL, Yao CW, Sheu LF, Chen A: Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma. Pathobiology; 2006;73(3):141-8
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma.
  • In nude mice, the growth of the tumor was inhibited by 30% by AS-CH or AS-AC (20 mg/kg; p < 0.05) and by 60% by AS-CH or AS-AC (60 mg/kg; p < 0.05).
  • CONCLUSIONS: Danggui may inhibit tumor growth by reducing the level of VEGF and the proapoptotic protein, cathepsin B.
  • [MeSH-major] Angelica sinensis / chemistry. Antineoplastic Agents / pharmacology. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Drugs, Chinese Herbal / pharmacology. Phytotherapy
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Cathepsin B / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Formazans / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Plant Extracts / pharmacology. Tetrazolium Salts / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085958.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Formazans; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 23305-68-2 / MTT formazan; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


12. Olivera M, Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, García-Martín E, Benítez J, Agúndez JA: Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma. Acta Neurol Scand; 2006 May;113(5):322-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma.
  • We investigated the association between the genetic NAT2 polymorphism and brain tumors by analysis of genomic DNA from 71 brain tumor patients and 258 healthy controls.
  • A higher number of individuals carrying functional NAT2 genes, and therefore with a rapid acetylation phenotype, was found in brain tumor patients vs healthy volunteers (OR 1.79, 95% CI 1.05-3.05; P < 0.05).
  • This is observed either for patients suffering from meningioma or astrocytoma, and this is due to an increase of the wild-type NAT2*4 allelic variant frequency (OR 1.48, 95% CI 0.99-2.19), and a reduction of the commonest defective allelic variant NAT2*5B in the brain tumor patients, compared with healthy subjects (OR 0.54, 95% CI 0.37-0.80).
  • CONCLUSIONS: This observation indicates that NAT2 could be considered as a low-penetrance gene for brain tumors, and that individuals carrying rapid acetylation alleles are at increased risk of developing brain tumors.
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Polymorphism, Single Nucleotide / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629768.001).
  • [ISSN] 0001-6314
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


13. Banerjee HN, Zhang L: Deciphering the finger prints of brain cancer astrocytoma in comparison to astrocytes by using near infrared Raman spectroscopy. Mol Cell Biochem; 2007 Jan;295(1-2):237-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deciphering the finger prints of brain cancer astrocytoma in comparison to astrocytes by using near infrared Raman spectroscopy.
  • To explore the biochemical differences between brain cancer cells Astrocytoma and normal cells Astrocyte, we investigated the Raman spectra of single cell from these two cell types and analyzed the difference in spectra and intensity.
  • The Raman spectra of brain cancer cells was similar to those of normal cells, but the Raman intensity of cancer cells was much higher than that of normal cells.
  • The Raman spectra of brain cancer Astrocytoma shows that the structural changes of cancer cells happen so that many biological functions of these cells are lost.
  • The results indicate that Raman spectra can offer the experimental basis for the cancer diagnosis and treatment.
  • [MeSH-major] Astrocytes / chemistry. Astrocytoma / chemistry. Brain Neoplasms / chemistry. Spectroscopy, Near-Infrared. Spectrum Analysis, Raman

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924417.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / G11HD 34280-05
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Liu RS, Chang CP, Chu LS, Chu YK, Hsieh HJ, Chang CW, Yang BH, Yen SH, Huang MC, Liao SQ, Yeh SH: PET imaging of brain astrocytoma with 1-11C-acetate. Eur J Nucl Med Mol Imaging; 2006 Apr;33(4):420-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET imaging of brain astrocytoma with 1-11C-acetate.
  • Images were analysed by visual interpretation and determination of the tumour to cortex ratio (T/C ratio) and standardised uptake value (SUV).
  • The tumour uptake was visually scored into three grades as compared with the contralateral cortex: clearly lower (-), almost equal (+) and clearly higher (++).
  • ACE is complementary to FDG for the diagnosis and characterisation of astrocytoma.
  • [MeSH-major] Acetates. Astrocytoma / diagnostic imaging. Brain Neoplasms / diagnostic imaging. Carbon. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CARBON .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurochem. 1968 Sep;15(9):965-70 [5682513.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] J Nucl Med. 2001 Aug;42(8):1243-50 [11483687.001]
  • [Cites] J Neurosci. 1998 Jul 15;18(14):5225-33 [9651205.001]
  • [Cites] J Nucl Med. 1995 Sep;36(9):1595-601 [7658216.001]
  • [Cites] J Nucl Med. 1986 Feb;27(2):235-8 [3712040.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):616-22 [2013802.001]
  • [Cites] J Comput Assist Tomogr. 1991 Sep-Oct;15(5):796-801 [1885797.001]
  • [Cites] Eur J Nucl Med. 1999 Nov;26(11):1501-9 [10552096.001]
  • [Cites] J Nucl Med. 1994 Oct;35(10 ):1653-5 [7931666.001]
  • [Cites] J Nucl Med. 1992 Apr;33(4):581-4 [1552344.001]
  • [Cites] Nucl Med Commun. 1999 Feb;20(2):131-4 [10088161.001]
  • [Cites] J Nucl Med. 2003 Feb;44(2):213-21 [12571212.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] Invest Radiol. 1987 May;22(5):360-71 [3496318.001]
  • [Cites] Int J Appl Radiat Isot. 1982 Jul;33(7):505-12 [6981606.001]
  • [Cites] Radiology. 1995 Apr;195(1):47-52 [7892494.001]
  • [Cites] Med Decis Making. 1992 Jan-Mar;12(1):60-75 [1538634.001]
  • [Cites] Neurology. 1991 Feb;41(2 ( Pt 1)):163-7 [1992357.001]
  • [Cites] Neurochem Int. 1993 Jan;22(1):19-29 [8095170.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):797 [14985862.001]
  • [Cites] Circulation. 1989 Jan;79(1):134-42 [2783396.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] Brain Res. 1992 Mar 27;576(1):120-4 [1515906.001]
  • [Cites] J Biol Chem. 1990 Aug 5;265(22):12916-26 [1973931.001]
  • [Cites] Eur J Nucl Med. 1996 May;23 (5):583-6 [8698067.001]
  • [Cites] J Nucl Med. 2002 Feb;43(2):181-6 [11850482.001]
  • (PMID = 16404596.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acetates; 0 / Radiopharmaceuticals; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


15. Gathinji M, McGirt MJ, Attenello FJ, Chaichana KL, Than K, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa A: Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surg Neurol; 2009 Mar;71(3):299-303, discussion 303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of preoperative depression and survival after resection of malignant brain astrocytoma.
  • It remains unclear if clinical depression affects survival after surgical management of malignant brain astrocytoma.
  • We set out to determine whether patients with a diagnosis of clinical depression before surgery experienced decreased survival independent of treatment modality or degree of disability.
  • METHODS: One thousand fifty-two patients undergoing surgical management for malignant brain astrocytoma (WHO grade 3 or 4) performed at a single institution from 1995 to 2006 were retrospectively reviewed.
  • Forty-nine patients (5%) carried the diagnosis of depression at the time of surgery.
  • CONCLUSION: In our experience, patients who are actively depressed at the time of surgery were associated with decreased survival after surgical management of malignant astrocytoma, independent of degree of disability, tumor grade, or subsequent treatment modalities.
  • [MeSH-major] Astrocytoma / mortality. Brain Neoplasms / mortality. Depression / mortality

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786716.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Chu SH, Yuan XH, Jiang PC, Li ZQ, Zhang J, Wen ZH, Zhao SY, Chen XJ, Cao CJ: [The expression of hepatocyte growth factor and its receptor in brain astrocytomas]. Zhonghua Yi Xue Za Zhi; 2005 Mar 30;85(12):835-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of hepatocyte growth factor and its receptor in brain astrocytomas].
  • OBJECTIVE: To investigate the expression of hepatocyte growth factor (HGF) mRNA and its receptor (c-Met) mRNA in brain astrocytomas and their relationships with tumor proliferation, angiogenesis, clinical pathology and prognosis.
  • METHODS: The expression of HGF mRNA, c-Met mRNA in the resected tumor tissues of 76 patients with brain astrocytomas, 43 males and 33 females, aged 20 - 71, were detected by in situ hybridization.
  • RESULTS: The positive rates of expression of HGF, c-Met and PCNA in low pathologic grades of brain astrocytoma were 34.5%, 44.8% and 15% +/- 9% respectively, and in high pathologic grades of brain astrocytoma were 34.5%, 44.8% and 48% +/- 12% respectively (P < 0.05).
  • MVD in low and high pathologic grades of brain astrocytoma were 17 +/- 7 and 31 +/- 13 respectively (P < 0.05).
  • The expression of HGF, c-Met, PCNA and CD34 was not related to sex, age, position of tumor and diameter of tumor.
  • The expression of c-Met was related to the expression of HGF, PCNA and the MVD in the tumor tissues of these patients.
  • The pathological grade, position of tumor, HGF, c-Met, PCNA, MVD had a significant influence on the survival time.
  • CONCLUSION: HGF/c-Met plays an important role in the formation and progression of the brain astrocytoma and can promote tumor proliferation and intratumoral microvascular formation, and is closely related to the prognosis of the patients.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Hepatocyte Growth Factor / biosynthesis. Proto-Oncogene Proteins / biosynthesis. Receptors, Growth Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic. Proto-Oncogene Proteins c-met. RNA, Messenger / biosynthesis. RNA, Messenger / genetics


17. Weber RG, Hoischen A, Ehrler M, Zipper P, Kaulich K, Blaschke B, Becker AJ, Weber-Mangal S, Jauch A, Radlwimmer B, Schramm J, Wiestler OD, Lichter P, Reifenberger G: Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene; 2007 Feb 15;26(7):1088-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular pathogenesis of pleomorphic xanthoastrocytoma (PXA), a rare astrocytic brain tumor with a relatively favorable prognosis, is still poorly understood.
  • Interphase fluorescence in situ hybridization to tissue sections confirmed the presence of tumor cells with homozygous 9p21.3 deletions.
  • [MeSH-major] Astrocytoma / genetics. Chromosome Deletion. Chromosomes, Human, Pair 9 / genetics. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gene Deletion. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins / deficiency

  • Genetic Alliance. consumer health - Chromosome 9.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909113.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein
  •  go-up   go-down


18. Lin ZX, Yang LJ, Huang Q, Fu J: Activated vascular endothelia regulate invasion of glioma cells through expression of fibronectin. Chin Med J (Engl); 2010 Jul;123(13):1754-61
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous researches have indicated that glioma invasion may occur within a tumor-host microecology, and that fibronectin may be involved in glioma invasion as an important component of the extracellular matrix.
  • However, how the interaction between tumor cells and vascular endothelial cells affects glioma invasion is poorly understood.
  • The aim of this study was to investigate the effects of the interaction between tumor cells and vascular endothelial cells on glioma invasion, and the relationship of this interaction to fibronectin.
  • METHODS: The localization of fibronectin in different brain astrocytoma tissues was determined by immunohistochemistry.
  • Additionally, the influence of the interaction between tumor cells and vascular endothelial cells on glioma cell invasion was determined by an in vitro rapid invasion test.
  • RESULTS: In brain astrocytoma tissues, fibronectin was present on the endothelial cells, in the extracellular matrix.
  • [MeSH-minor] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Movement / physiology. Cells, Cultured. Coculture Techniques. Enzyme-Linked Immunosorbent Assay. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819642.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Fibronectins
  •  go-up   go-down


19. Distelmaier F, Janssen G, Mayatepek E, Schaper J, Göbel U, Rosenbaum T: Disseminated pilocytic astrocytoma involving brain stem and diencephalon: a history of atypical eating disorder and diagnostic delay. J Neurooncol; 2006 Sep;79(2):197-201
MedlinePlus Health Information. consumer health - Eating Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated pilocytic astrocytoma involving brain stem and diencephalon: a history of atypical eating disorder and diagnostic delay.
  • The association of weight loss and pediatric brain tumors that affect the diencephalon or brain stem with weight loss is a recognized, but not fully understood phenomenon.
  • Tumors that compress or infiltrate the brain stem rarely cause both psychological disturbance and emaciation.
  • In this report we present an unusual case of severe emaciation in a 4(9)/(12)-year-old girl with a juvenile pilocytic astrocytoma of the hypothalamic region and brain stem with neuroaxis dissemination.
  • This case illustrates the importance of considering intracranial mass-lesions in the differential diagnosis of weight loss, psychological disturbance and atypical eating disorder.
  • We discuss the importance of tumor multifocality and the role of patient age in the clinical presentation with reference to the literature.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Emaciation / etiology. Feeding and Eating Disorders / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Stem / pathology. Child, Preschool. Diagnosis, Differential. Feeding and Eating Disorders of Childhood / diagnosis. Female. Humans. Hypothalamus / pathology. Spinal Cord Neoplasms / complications. Spinal Cord Neoplasms / secondary. Treatment Outcome


20. Kumar AJ, Leeds NE, Kumar VA, Fuller GN, Lang FF, Milas Z, Weinberg JS, Ater JL, Sawaya R: Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas. J Comput Assist Tomogr; 2010 Jul;34(4):601-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas.
  • OBJECTIVE: The typical magnetic resonance/computed tomographic imaging appearance of pilocytic astrocytoma (PA) is that of a cyst with an intensely enhancing mural nodule.
  • METHODS: One hundred patients referred to the cancer center with brain tumors histologically proven to be PA were retrospectively reviewed (95 by magnetic resonance imaging and 5 by computed tomographic imaging) and analyzed.
  • Tumor locations consisted of the following: optic chiasm (22), lateral ventricle (3), thalamus (12), basal ganglia (1), cerebral hemisphere (10), corpus callosum (2), brain stem (26), fourth ventricle (1), and cerebellum (23).
  • CONCLUSIONS: It is important to recognize the aggressive imaging appearance of PA (grade 1 astrocytoma) because it can be mistaken for high-grade gliomas and may thus lead to inappropriate therapy.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Brain / pathology. Brain / radiography. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed / methods. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657231.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Gong Y, Zhang Z: CellFrame: a data structure for abstraction of cell biology experiments and construction of perturbation networks. Ann N Y Acad Sci; 2007 Dec;1115:249-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have implemented an initial version of CellFrame, which contains data collected from reported experiments on human brain astrocytoma and colorectal cancer cell lines (http://cellframe.bioknowledge.org).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925354.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteome
  •  go-up   go-down


22. Brassesco MS, Valera ET, Becker AP, Castro-Gamero AM, de Aboim Machado A, Santos AC, Scrideli CA, Oliveira RS, Machado HR, Tone LG: Low-grade astrocytoma in a child with encephalocraniocutaneous lipomatosis. J Neurooncol; 2010 Feb;96(3):437-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade astrocytoma in a child with encephalocraniocutaneous lipomatosis.
  • Encephalocutaneous lipomatosis (ECCL), or Haberland syndrome, is an uncommon congenital disorder with unique cutaneous, ocular and neurological features.
  • Cytogenetic analysis from tumor sample was also performed.
  • This is the first report of a low-grade astrocytoma occurring in a child with ECCL.
  • Whether or not the origin of the tumor is associated to the pathogenesis of the underlying syndrome is a matter for further investigation.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Lipomatosis / complications. Neurocutaneous Syndromes / complications

  • Genetic Alliance. consumer health - Encephalocraniocutaneous Lipomatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652916.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Magalhaes A, Godfrey W, Shen Y, Hu J, Smith W: Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol; 2005 Jan;12(1):51-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopy of brain tumors correlated with pathology.
  • RATIONALE AND OBJECTIVES: Evaluate proton magnetic resonance spectroscopy ((1)H-MRS) for assessing and grading brain tumors.
  • In 16 patients with brain astrocytoma of various grades, the pathology grading was correlated with Cho/NAA and Cho/Cr.
  • These values were 6.53 and 3.35 for nine patients with Grade 4 astrocytoma; 1.85 and 1.62 for three patients with Grade 3 astrocytoma; 2.21 and 1.50 for three patients with Grade 2 astrocytoma; and 1.45 and 1.49 for one patient with Grade 1 astrocytoma.
  • CONCLUSION: MRS ratios can be used to differentiate malignant and nonmalignant lesions from normal brain tissue.
  • In general, high-grade astrocytoma have higher Cho/NAA and Cho/Cr ratios compared with low-grade astrocytoma.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / pathology. Brain / pathology. Choline / analysis. Creatine / analysis. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Glioma / diagnosis. Glioma / pathology. Gliosarcoma / diagnosis. Gliosarcoma / pathology. Humans. Hydrogen. Image Processing, Computer-Assisted / methods. Male. Middle Aged. Oligodendroglioma / diagnosis. Oligodendroglioma / pathology. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691725.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; 7YNJ3PO35Z / Hydrogen; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


24. Dashti SR, Robinson S, Rodgers M, Cohen AR: Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report. J Neurosurg; 2005 Apr;102(3 Suppl):322-5
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report.
  • Tuberous sclerosis complex is a genetic disorder characterized by the development of hamartomas in multiple organs including the brain, skin, eye, kidney, and heart.
  • Cortical tubers and subependymal nodules are the characteristic intracranial lesions of tuberous sclerosis.
  • Pathological examination showed a giant cell astrocytoma.
  • To the authors' knowledge, this is the first reported case of tuberous sclerosis associated with a giant cell astrocytoma of the pineal region.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / surgery. Pinealoma / complications. Pinealoma / surgery. Tuberous Sclerosis / complications
  • [MeSH-minor] Cell Transformation, Neoplastic / pathology. Child, Preschool. Eye Abnormalities / complications. Eye Abnormalities / diagnosis. Eye Abnormalities / genetics. Follow-Up Studies. Humans. Image Enhancement. Magnetic Resonance Imaging. Male. Microsurgery. Neuroendoscopes. Neurologic Examination. Pineal Gland / pathology. Pineal Gland / surgery. Postoperative Complications / diagnosis

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881760.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Lu Z, Cao Y, Wang Y, Zhang Q, Zhang X, Wang S, Li Y, Xie H, Jiao B, Zhang J: Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China. J Neurooncol; 2007 Oct;85(1):65-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China.
  • The single nucleotide polymorphisms (SNPs) in the promoter region of matrix metalloproteinase (MMP) genes may influence tumor occurrence and progression via modifying mRNA transcription and protein expression.
  • The study aims to explore the association of the SNPs in MMP-1, 3 and MMP-9 promoters with susceptibility to adult brain astrocytoma in northern China.
  • Genotyping for the MMP-1 -1607 2G/1G, MMP-3 -1171 5A/6A, and MMP-9 -1562 C/T SNPs were performed by PCR-RFLP methods among 236 adult astrocytoma patients and 366 healthy controls.
  • The results showed that the overall distribution of the MMP-1 allelotype and genotype among astrocytoma patients and healthy controls was significantly different (P = 0.002 and P < 0.001, respectively).
  • Compared with the 2G/2G genotype, the 1G/1G genotype significantly decreased the risk of astrocytoma development (adjusted OR = 0.58, 95% CI = 0.42-0.79).
  • The similar results were obtained when stratified by gender and age at tumor diagnosis (< or =45 or >45 years).
  • The association between MMP-3 -1171 5A/6A or MMP-9 -1562 C/T SNPs and susceptibility to astrocytoma was not observed in this study.
  • However, MMP-1 1G-MMP-3 6A haplotype significantly reduced the risk of astrocytoma development when using MMP-1 2G-MMP-3 6A haplotype as a reference (OR = 0.45, 95% CI = 0.29-0.67).
  • The present study suggested that, the MMP-1 -1607 1G/1G genotype and MMP-1 1G-MMP-3 6A haplotype may play protective role in the development of adult astrocytoma in northern Chinese, whereas the MMP-3 -1171 5A/6A and MMP-9 -1562 C/T polymorphisms may not be independent factors to influence susceptibility to adult astrocytoma in this population.
  • [MeSH-major] Astrocytoma / epidemiology. Astrocytoma / genetics. Brain Neoplasms / epidemiology. Brain Neoplasms / genetics. Matrix Metalloproteinase 1 / genetics. Matrix Metalloproteinase 3 / genetics. Matrix Metalloproteinase 9 / genetics. Polymorphism, Genetic / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Case-Control Studies. China / epidemiology. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Genetic Linkage / genetics. Genotype. Haplotypes. Humans. Polymorphism, Single Nucleotide. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502998.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


26. Walid MS, Troup EC: Cerebellar anaplastic astrocytoma in a teenager with Ollier Disease. J Neurooncol; 2008 Aug;89(1):59-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar anaplastic astrocytoma in a teenager with Ollier Disease.
  • INTRODUCTION: Ollier Disease is a sporadic skeletal disorder with a predisposition to oncogenesis.
  • We are presenting a young patient with Ollier Disease and high-grade astrocytoma.
  • Brain MRI with contrast showed a 41 x 55 mm mass in the posterior fossa with spotty enhancement, which pathology proved to be anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / etiology. Astrocytoma / pathology. Cerebellar Neoplasms / etiology. Cerebellar Neoplasms / pathology. Cerebellum / pathology. Enchondromatosis / complications

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Ollier disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414790.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / PTH1R protein, human; 0 / Receptor, Parathyroid Hormone, Type 1; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


27. Axelsen JB, Lotem J, Sachs L, Domany E: Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc Natl Acad Sci U S A; 2007 Aug 7;104(32):13122-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cancers analyzed include brain (astrocytoma and glioblastoma), breast, colon, endometrium, kidney, liver, lung, ovary, prostate, skin, and thyroid cancers.
  • Different types of cancers, including different brain cancers arising from the same lineage, showed differences in the tissue-selective genes they overexpressed.
  • Melanomas overexpressed the highest number of brain-selective genes and this may contribute to melanoma metastasis to the brain.
  • Of all of the genes with tissue-selective expression, those selectively expressed in testis showed the highest frequency of genes that are overexpressed in at least two types of cancer.
  • Cancers aberrantly expressing such genes may acquire phenotypic alterations that contribute to cancer cell viability, growth, and metastasis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2238-42 [12399967.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5):513-7 [12407516.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:496-501 [12454644.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):825-33 [12724292.001]
  • [Cites] Cancer Immun. 2004 Jan 23;4:1 [14738373.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1799-806 [12969976.001]
  • [Cites] Curr Opin Oncol. 2004 May;16(3):211-4 [15069314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16022-7 [15505217.001]
  • [Cites] PLoS Biol. 2004 Dec;2(12):e427 [15562319.001]
  • [Cites] Bioinformatics. 2005 Mar 1;21(5):650-9 [15388519.001]
  • [Cites] DNA Res. 2004 Oct 31;11(5):335-44 [15747581.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2390-7 [15832406.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):703-13 [15963951.001]
  • [Cites] Genomics. 2005 Aug;86(2):127-41 [15950434.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7234-42 [16243793.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18556-61 [16339305.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19069-74 [16354839.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):820-7 [16424014.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):51-61 [16436634.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):121-32 [16473279.001]
  • [Cites] Endocrinology. 2006 Mar;147(3):1097-121 [16306079.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2129-37 [16489013.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Neurogenetics. 2006 May;7(2):67-80 [16572319.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5278-86 [16707453.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Jul;35(1):65-71 [16498083.001]
  • [Cites] BMC Genomics. 2006;7:92 [16638148.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Oncogene. 2006 Dec 14;25(59):7663-72 [16847453.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [ErratumIn] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15168. Bock-Axelsen, Jacob [corrected to Bock, Jacob Bock]
  • (PMID = 17664417.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1941809
  •  go-up   go-down


28. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quiñones-Hinojosa AR: Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg; 2009 Jan;110(1):156-62
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
  • OBJECT: With recent advances in the adjuvant treatment of malignant brain astrocytomas, it is increasingly debated whether extent of resection affects survival.
  • METHODS: The authors retrospectively reviewed the cases of 1215 patients who underwent surgery for malignant brain astrocytomas (World Health Organization [WHO] Grade III or IV) at a single institution from 1996 to 2006.
  • Surgery consisted of primary resection in 549 patients (58%) and revision resection for tumor recurrence in 400 patients (42%).
  • Adjusting for factors associated with survival for WHO Grade III astrocytoma (age, KPS score, and revision resection), GTR versus STR (p < 0.05) was associated with improved survival.
  • CONCLUSIONS: In the authors' experience with both primary and secondary resection of malignant brain astrocytomas, increasing extent of resection was associated with improved survival independent of age, degree of disability, WHO grade, or subsequent treatment modalities used.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847342.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Polyesters; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


29. Eddaoudi A, Townsend-Nicholson A, Timms JF, Schorge S, Jayasinghe SN: Molecular characterisation of post-bio-electrosprayed human brain astrocytoma cells. Analyst; 2010 Oct;135(10):2600-12
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterisation of post-bio-electrosprayed human brain astrocytoma cells.
  • [MeSH-minor] Astrocytoma. Brain Neoplasms. Calcium / metabolism. Cell Survival. Electrophoresis, Gel, Two-Dimensional. Humans. Indoles / pharmacology. Maleimides / pharmacology. Potassium Channels / metabolism. Receptor, Muscarinic M3 / genetics. Receptor, Muscarinic M3 / metabolism. Transfection. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694206.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601440; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indoles; 0 / Maleimides; 0 / Potassium Channels; 0 / Receptor, Muscarinic M3; 0 / Tumor Necrosis Factor-alpha; 0 / bisindolylmaleimide VIII; SY7Q814VUP / Calcium
  •  go-up   go-down


30. Habek M, Brinar VV, Rados M, Zadro I, Zarković K: Brain MRI abnormalities in ataxia-telangiectasia. Neurologist; 2008 May;14(3):192-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain MRI abnormalities in ataxia-telangiectasia.
  • BACKGROUND: Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder, initially characterized by normal brain magnetic resonance imaging (MRI).
  • DISCUSSION: In our patient, brain MRI confirmed extensive extracerebellar lesions in AT.
  • CONCLUSION: Our report broadens the spectrum of brain MRI abnormalities in AT and supports the hypothesis on cerebrovascular abnormalities occurring in later stages of AT.
  • [MeSH-major] Astrocytoma / pathology. Ataxia Telangiectasia / pathology. Brain / abnormalities. Brain / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Atrophy / pathology. Atrophy / physiopathology. Cerebellar Diseases / etiology. Cerebellar Diseases / pathology. Cerebellar Diseases / physiopathology. Cerebral Arteries / pathology. Cerebral Arteries / physiopathology. Disease Progression. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Telangiectasis / genetics. Telangiectasis / pathology. Telangiectasis / physiopathology. Tomography, X-Ray Computed


31. Rashid MH, Ahmad SU, Rahman MH, Raihan MZ, Sayed MA: Surgical outcome of low grade astrocytoma of brain. Mymensingh Med J; 2010 Apr;19(2):185-90
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of low grade astrocytoma of brain.
  • This study was carried out in the department of Neurosurgery, Dhaka Medical College Hospital, Dhaka, Bangladesh, during the period of January 2003 to December 2006 to elucidate the effectiveness of surgical treatment in the management of low grade astrocytoma of brain.
  • For this purpose, a total number of 50 cases admitted during the study period with low grade astrocytoma of brain supported by clinical features and radiological investigations (CT and MRI scan) were included in this study.
  • Out of 50 patients 60.0% had gross total removal of tumor and 40.0% sub total tumor resection.
  • Histopathological study was done in all cases after tumor resection.
  • Among the gross total tumor removal cases highest percentage had good recovery (93.4%) in the immediate post operative period.
  • Another 2(4.0%), those underwent subtotal tumor resection died during subsequent follow up period at 8th and 14th postoperative day.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395910.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


32. Seyfried TN, Mukherjee P: Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab (Lond); 2005 Oct 21;2:30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting energy metabolism in brain cancer: review and hypothesis.
  • Malignant brain tumors are a significant health problem in children and adults and are often unmanageable.
  • As a metabolic disorder involving the dysregulation of glycolysis and respiration, malignant brain cancer is potentially manageable through changes in metabolic environment.
  • A radically different approach to brain cancer management is proposed that combines metabolic control analysis with the evolutionarily conserved capacity of normal cells to survive extreme shifts in physiological environment.
  • In contrast to malignant brain tumors that are largely dependent on glycolysis for energy, normal neurons and glia readily transition to ketone bodies (beta-hydroxybutyrate) for energy in vivo when glucose levels are reduced.
  • The bioenergetic transition from glucose to ketone bodies metabolically targets brain tumors through integrated anti-inflammatory, anti-angiogenic, and pro-apoptotic mechanisms.
  • The approach focuses more on the genomic flexibility of normal cells than on the genomic defects of tumor cells and is supported from recent studies in orthotopic mouse brain tumor models and in human pediatric astrocytoma treated with dietary energy restriction and the ketogenic diet.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1990 Jan;26(1):1-19 [2403663.001]
  • [Cites] J Neurosurg Sci. 1989 Jan-Mar;33(1):55-64 [2674359.001]
  • [Cites] Cell Biochem Funct. 1989 Jan;7(1):11-9 [2752533.001]
  • [Cites] Neurosurgery. 1986 Dec;19(6):896-9 [3027607.001]
  • [Cites] Baillieres Clin Gastroenterol. 1988 Oct;2(4):941-9 [3072982.001]
  • [Cites] J Gerontol. 1988 Mar;43(2):B40-2 [3346517.001]
  • [Cites] Metab Brain Dis. 1986 Dec;1(4):279-91 [3508247.001]
  • [Cites] Prog Exp Tumor Res. 1972;17:163-91 [4343199.001]
  • [Cites] N Engl J Med. 1970 Mar 19;282(12):668-75 [4915800.001]
  • [Cites] J Clin Invest. 1967 Oct;46(10):1589-95 [6061736.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Nov;78(11):7214-8 [6118869.001]
  • [Cites] Fed Proc. 1983 Sep;42(12):2875-80 [6136420.001]
  • [Cites] Cancer Biochem Biophys. 1984 Jun;7(2):101-7 [6147189.001]
  • [Cites] Ann Neurol. 1983 Dec;14(6):614-26 [6606389.001]
  • [Cites] J Neurosci Res. 1982;8(4):671-82 [7161845.001]
  • [Cites] Genetics. 1981 Mar-Apr;97(3-4):639-66 [7297851.001]
  • [Cites] J Neurooncol. 1995;24(2):153-61 [7562002.001]
  • [Cites] J Am Diet Assoc. 1995 Jun;95(6):693-7 [7759747.001]
  • [Cites] FASEB J. 1995 May;9(8):651-8 [7768357.001]
  • [Cites] J Am Coll Nutr. 1995 Apr;14(2):202-8 [7790697.001]
  • [Cites] Brain Res Mol Brain Res. 1994 Nov;27(1):51-7 [7877454.001]
  • [Cites] Diabetologia. 1993 Nov;36(11):1191-7 [8270135.001]
  • [Cites] Prog Neurobiol. 1993 Feb;40(2):163-221 [8430212.001]
  • [Cites] Biochimie. 1996;78(3):155-64 [8831946.001]
  • [Cites] Biochem J. 1996 Oct 15;319 ( Pt 2):477-82 [8912684.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):1903-11 [9216643.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1763-73 [9392617.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3990-5 [9520480.001]
  • [Cites] Am J Pathol. 1955 Jan-Feb;31(1):1-29 [13218129.001]
  • [Cites] J Natl Cancer Inst. 1958 Sep;21(3):485-94 [13576102.001]
  • [Cites] J Biol Chem. 1964 Jan;239:18-30 [14114842.001]
  • [Cites] Nutr Rev. 2003 Oct;61(10):327-41 [14604265.001]
  • [Cites] Carcinogenesis. 2004 Jul;25(7):1157-63 [14963017.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2213-7 [15330163.001]
  • [Cites] Oncologist. 2004;9(5):528-37 [15477637.001]
  • [Cites] J Neurosci Res. 2005 Jan 1-15;79(1-2):55-64 [15573400.001]
  • [Cites] J Neurosci Res. 2005 Jan 1-15;79(1-2):139-45 [15578721.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):557-64 [15687310.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1077-84 [15746164.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22706-14 [15855169.001]
  • [Cites] Mech Ageing Dev. 2005 Sep;126(9):960-6 [15927235.001]
  • [Cites] Arch Neurol. 1998 Jul;55(7):922-8 [9678309.001]
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 1):E516-24 [9725820.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Sep;19(3):462-9 [9730874.001]
  • [Cites] J Nutr. 1999 Feb;129(2S Suppl):571S-574S [10064335.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):512-23 [10088621.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):429-32 [10199330.001]
  • [Cites] Science. 1999 Dec 3;286(5446):1832-4 [10610570.001]
  • [Cites] Prog Lipid Res. 2000 May;39(3):257-88 [10799718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5440-4 [10805800.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2189-200 [10873068.001]
  • [Cites] Mol Carcinog. 2000 Dec;29(4):205-11 [11170258.001]
  • [Cites] Neurochem Int. 2001 May;38(6):519-27 [11248400.001]
  • [Cites] Nat Rev Genet. 2001 May;2(5):383-7 [11331904.001]
  • [Cites] J Mol Neurosci. 2001 Feb;16(1):1-12 [11345515.001]
  • [Cites] Perspect Biol Med. 2001 Spring;44(2):263-82 [11370160.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] IUBMB Life. 2001 Apr;51(4):241-7 [11569918.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] Science. 2002 Apr 26;296(5568):701-3 [11976445.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1615-21 [12085212.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):836-43 [12223427.001]
  • [Cites] Neurobiol Aging. 2002 Sep-Oct;23(5):707-17 [12392776.001]
  • [Cites] Microsc Res Tech. 2002 Nov 15;59(4):264-72 [12424787.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):151-60 [12622454.001]
  • [Cites] Nat Biotechnol. 2003 May;21(5):477-9 [12721560.001]
  • [Cites] Nutr Neurosci. 2003 Apr;6(2):67-79 [12722982.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1225-31 [12807724.001]
  • [Cites] Trans Am Clin Climatol Assoc. 2003;114:149-61; discussion 162-3 [12813917.001]
  • [Cites] J Neurochem. 2003 Aug;86(3):529-37 [12859666.001]
  • [Cites] BMC Cancer. 2005;5:102 [16105171.001]
  • [Cites] J Neurosci. 2003 Jul 2;23(13):5928-35 [12843297.001]
  • [Cites] Free Radic Biol Med. 2003 Sep 15;35(6):626-35 [12957655.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1375-82 [14520474.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):309-19 [14769489.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5622-9 [15328205.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 5;324(1):269-75 [15465013.001]
  • [Cites] J Neurosci. 2005 Jan 26;25(4):848-59 [15673665.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):615-7 [15687318.001]
  • [Cites] J Neurosci Res. 2005 May 15;80(4):501-9 [15825191.001]
  • [Cites] J Inherit Metab Dis. 2005;28(2):109-21 [15877199.001]
  • [Cites] J Neurochem. 2005 Jun;93(5):1327-33 [15934951.001]
  • [Cites] Physiol Rev. 1979 Jul;59(3):527-605 [37532.001]
  • [Cites] Prog Exp Tumor Res. 1978;22:190-274 [149996.001]
  • [Cites] J Neurochem. 1978 Dec;31(6):1529-31 [298319.001]
  • [Cites] Aust J Exp Biol Med Sci. 1979 Oct;57(5):529-39 [548019.001]
  • [Cites] Neurol Res. 1992 Sep;14(4):289-93 [1360622.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):3972-9 [1617673.001]
  • [Cites] J Neurooncol. 1990 Aug;9(1):17-28 [2213113.001]
  • (PMID = 16242042.001).
  • [ISSN] 1743-7075
  • [Journal-full-title] Nutrition & metabolism
  • [ISO-abbreviation] Nutr Metab (Lond)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102135; United States / NICHD NIH HHS / HD / R01 HD039722
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1276814
  •  go-up   go-down


33. Tanaka KF, Ochi N, Hayashi T, Ikeda E, Ikenaka K: Fluoro-Jade: new fluorescent marker of Rosenthal fibers. Neurosci Lett; 2006 Oct 23;407(2):127-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluoro Jade-positive masses were seen in samples of Alexander disease brain, pilocytic astrocytoma, and in brain tissue from a mouse model of Alexander disease.
  • [MeSH-minor] Animals. Astrocytoma / pathology. Brain / pathology. Brain Diseases / pathology. Fluoresceins. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Mice. Mice, Transgenic. Microscopy, Confocal. Organic Chemicals. Tissue Embedding. Tissue Fixation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949206.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Fluoresceins; 0 / Fluorescent Dyes; 0 / Glial Fibrillary Acidic Protein; 0 / Organic Chemicals; 0 / fluoro jade
  •  go-up   go-down


34. Seyfried BT, Kiebish M, Marsh J, Mukherjee P: Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet. J Cancer Res Ther; 2009 Sep;5 Suppl 1:S7-15
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet.
  • Malignant brain tumors are a significant health problem in children and adults and are largely unmanageable.
  • As a metabolic disorder involving the dysregulation of glycolysis and respiration (the Warburg effect), malignant brain cancer can be managed through changes in metabolic environment.
  • In contrast to malignant brain tumors that are mostly dependent on glycolysis for energy, normal neurons and glia readily transition to ketone bodies (beta-hydroxybutyrate) for energy in vivo when glucose levels are reduced.
  • We propose a different approach to brain cancer management that exploits the metabolic flexibility of normal cells at the expense of the genetically defective and less metabolically flexible tumor cells.
  • This approach to brain cancer management is supported from recent studies in orthotopic mouse brain tumor models and in human pediatric astrocytoma treated with calorie restriction and the ketogenic diet.
  • [MeSH-major] Brain Neoplasms / metabolism. Caloric Restriction. Energy Metabolism / physiology. Ketogenic Diet

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009300.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102135; United States / NICHD NIH HHS / HD / HD39722
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] India
  • [Number-of-references] 150
  •  go-up   go-down


35. Tchaicha JH, Mobley AK, Hossain MG, Aldape KD, McCarty JH: A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis. Oncogene; 2010 Aug 5;29(31):4460-72
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis.
  • Furthermore, little is known about how cancer cells selectively circumvent the actions of these inhibitors to promote pathological angiogenesis, a requisite event for tumor progression.
  • Using mosaic mouse models of the malignant brain cancer, astrocytoma, we report that tumor cells induce pathological angiogenesis by suppressing expression of the ECM protein receptor alphavbeta8 integrin.
  • Diminished integrin expression in astrocytoma cells leads to reduced activation of latent TGFbetas, resulting in impaired TGFbeta receptor signaling in tumor-associated endothelial cells.
  • These data reveal that astrocytoma cells manipulate their angiogenic balance by selectively suppressing alphavbeta8 integrin expression and function.
  • Finally, these results show that an adhesion and signaling axis normally involved in developmental brain angiogenesis is pathologically exploited in adult brain tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Methods Enzymol. 2006;419:3-23 [17141049.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] J Cell Sci. 2007 May 15;120(Pt 10):1810-7 [17502485.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78 [17522591.001]
  • [Cites] Glia. 2007 Aug 1;55(10):1023-33 [17549683.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Mech Dev. 2008 May-Jun;125(5-6):508-16 [18343643.001]
  • [Cites] Am J Pathol. 2008 Jun;172(6):1740-7 [18467691.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3308-16 [19351861.001]
  • [Cites] Curr Opin Hematol. 2009 May;16(3):209-14 [19318941.001]
  • [Cites] J Cell Sci. 2009 Jun 1;122(Pt 11):1842-51 [19461074.001]
  • [Cites] Cell Adh Migr. 2009 Apr-Jun;3(2):199-204 [19363295.001]
  • [Cites] Cell Adh Migr. 2009 Apr-Jun;3(2):211-5 [19372738.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):9-22 [20029421.001]
  • [Cites] Oncogene. 2010 Mar 4;29(9):1351-61 [20010874.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):4956-60 [11431323.001]
  • [Cites] Mol Cell Neurosci. 2001 Jul;18(1):108-18 [11461157.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6674-8 [11559533.001]
  • [Cites] Development. 2002 Jun;129(12):2891-903 [12050137.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5551-8 [12359767.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(21):7667-77 [12370313.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1962-8 [12702589.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2751-8 [15087390.001]
  • [Cites] Anal Biochem. 1994 Feb 1;216(2):276-84 [8179182.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2746-51 [7796398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8502-7 [8710899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8761-6 [9238051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12081-7 [9342366.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Development. 2005 Jan;132(1):165-76 [15576410.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1883-94 [15920172.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13479-83 [16157875.001]
  • [Cites] Curr Top Dev Biol. 2005;69:67-99 [16243597.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1379-87 [16251422.001]
  • [Cites] J Neurosci. 2005 Oct 26;25(43):9940-8 [16251442.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • (PMID = 20531304.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NINDS NIH HHS / NS / R01 NS059876-03; United States / NINDS NIH HHS / NS / R01NS059876; United States / NCI NIH HHS / CA / P50CA127001; United States / NINDS NIH HHS / NS / R01 NS059876-02S2; United States / NINDS NIH HHS / NS / R01 NS059876; United States / NCI NIH HHS / CA / P50 CA127001; United States / NINDS NIH HHS / NS / NS059876-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrins; 0 / integrin alphavbeta8
  • [Other-IDs] NLM/ NIHMS198457; NLM/ PMC3037767
  •  go-up   go-down


36. Hariharan S, Donahue JE, Garre C, Origone P, Grewal RP: Clinicopathologic and genetic analysis of siblings with NF1 and adult-onset gliomas. J Neurol Sci; 2006 Aug 15;247(1):105-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neurofibromatosis Type 1 (NF1) is a common autosomal dominant neurogenetic disorder characterized by neoplasms involving the nervous system which typically present in children.
  • The development of intracranial tumors in adults with NF1 is uncommon and to our knowledge, siblings with adult onset gliomas have not been previously reported.
  • OBJECTIVE: To perform pathological, clinical and genetic analysis of an unusual family with NF1 and adult onset intracranial gliomas.
  • RESULTS: A 39-year-old woman presented with seizures and aphasia and was diagnosed with an intracerebral tumor.
  • In spite of therapy, she died from complications of tumor recurrence.
  • Although she did not meet the accepted clinical criteria for NF1, given that she has a sibling with NF1 and a malignancy observed in this disorder, we hypothesize that she also has NF1.
  • Our genetic analysis indicated a shared haplotype in these siblings who developed brain tumors but not in an unaffected sister suggesting that both carry the NF1 disease-producing allele.
  • CONCLUSION: NF1 should be a diagnostic consideration when siblings develop intracranial brain tumors even when they develop in adults.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Neurofibromatosis 1 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16725158.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


37. Necesalová E, Vranová V, Kuglík P, Cejpek P, Jarosová M, Pesáková M, Relichová J, Veselská R: Incidence of the main genetic markers in glioblastoma multiforme is independent of tumor topology. Neoplasma; 2007;54(3):212-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of the main genetic markers in glioblastoma multiforme is independent of tumor topology.
  • Glioblastoma multiforme (GBM) is the most common as well as the most aggressive type of primary brain tumor of astrocytic origin in adults.
  • Trisomy/polysomy of chromosome 7, monosomy of chromosome 10, EGFR gene amplification and p53 deletion have been described as the typical genetic markers for tumor classification and prediction of possible response to therapy.
  • Chromosomal abnormalities in tumor samples from a group of 21 patients surgically treated for GBM were characterized by means of the interphase-fluorescence in situ hybridization (I-FISH) technique using sets of centromere and locus-specific DNA probes.
  • In addition, we performed a detailed analysis of one selected tumor sample using a genomic microarray system (GenoSensor Array 300) to characterize copy number changes of specific sequences and refine results obtained by I-FISH.
  • However, the data show no significant differences in occurrence of the described genetic markers in either part of the tumor.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 10 / genetics. Glioblastoma / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Chromosome Aberrations. Chromosome Mapping. Female. Gene Amplification. Gene Dosage. Genetic Markers / genetics. Humans. In Situ Hybridization, Fluorescence. Incidence. Karyotyping. Male. Middle Aged. Nucleic Acid Hybridization. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447852.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


38. Hlobilkova A, Ehrmann J, Knizetova P, Krejci V, Kalita O, Kolar Z: Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. Neoplasma; 2009;56(4):284-90
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression.
  • Astrocytomas, particularly high grade astrocytoma, are brain tumors with potent angiogenic activity.
  • Our immnunohistochemical study assessed vascular endothelial growth factor (VEGF), VEGF receptors (Flk-1, and Flt-1), the intermediate filamental protein nestin which plays a role in central nervous system development, and MMP-9, which belongs the family of matrix metalloproteinases implicated in tumor invasion and angiogenesis regulation.
  • We investigated the expression of VEGF, its receptors, nestin and MMP-9 in astrocytomas and their correlation with tumor grade.
  • Expression of Flt-1 and Flk-1 showed no significant differences between low and high grade tumor groups.
  • Nestin expression in tumor astrocytes and endothelial cells increased in high grade group (p same 0.007 and 0.003).
  • Expression of nestin and MMP-9 also suggest their likely role in astrocytoma vascular development and proliferation.
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Intermediate Filament Proteins / metabolism. Matrix Metalloproteinase 9 / metabolism. Nerve Tissue Proteins / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473053.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


39. Pantelis E, Papadakis N, Verigos K, Stathochristopoulou I, Antypas C, Lekas L, Tzouras A, Georgiou E, Salvaras N: Integration of functional MRI and white matter tractography in stereotactic radiosurgery clinical practice. Int J Radiat Oncol Biol Phys; 2010 Sep 1;78(1):257-67
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: fMRI and tractography data sets were acquired and fused with corresponding anatomical MR and computed tomography images of patients with arteriovenous malformation (AVM), astrocytoma, brain metastasis, or hemangioma and referred for stereotactic radiosurgery.
  • In the astrocytoma case, the dose to the motor cortex bordering the lesion was reduced to 1,900 cGy from 2,100 cGy, and therefore, the biologically equivalent dose in three fractions was delivered instead.
  • [MeSH-major] Brain Neoplasms. Intracranial Arteriovenous Malformations. Magnetic Resonance Imaging / methods. Radiation Injuries / prevention & control. Radiosurgery / methods
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / radiography. Astrocytoma / surgery. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / radiography. Brain Stem Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Diffusion Tensor Imaging / methods. Female. Hemangioma, Cavernous, Central Nervous System / pathology. Hemangioma, Cavernous, Central Nervous System / radiography. Hemangioma, Cavernous, Central Nervous System / surgery. Humans. Lung Neoplasms / pathology. Male. Middle Aged. Motor Cortex / anatomy & histology. Motor Cortex / radiation effects. Motor Cortex / radiography. Pyramidal Tracts / anatomy & histology. Pyramidal Tracts / radiation effects. Pyramidal Tracts / radiography. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted / methods. Visual Pathways / anatomy & histology. Visual Pathways / radiation effects. Visual Pathways / radiography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20421146.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Gallagher A, Grant EP, Madan N, Jarrett DY, Lyczkowski DA, Thiele EA: MRI findings reveal three different types of tubers in patients with tuberous sclerosis complex. J Neurol; 2010 Aug;257(8):1373-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with Type C tuber dominance have more MRI abnormalities such as subependymal giant cell tumors, and were more likely to have an autism spectrum disorder, a history of infantile spasms, and a higher frequency of epileptic seizures, compared to patients who have a dominance in Type B tubers, and especially to those with a Type A dominance.

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2000 May 23;54(10):1976-84 [10822440.001]
  • [Cites] Neurology. 2009 Mar 31;72(13):1165-9 [19332694.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Jan;163(1):253-8 [11208653.001]
  • [Cites] Brain Dev. 2001 Nov;23(7):502-7 [11701245.001]
  • [Cites] Eur Radiol. 2002 Jan;12(1):138-43 [11868090.001]
  • [Cites] Epilepsy Res. 2003 Jan;52(3):203-13 [12536053.001]
  • [Cites] Psychol Med. 2003 Feb;33(2):335-44 [12622312.001]
  • [Cites] Arch Neurol. 2003 Nov;60(11):1580-4 [14623730.001]
  • [Cites] Arch Dis Child. 2004 Jun;89(6):530-3 [15155396.001]
  • [Cites] Neurology. 2004 Oct 26;63(8):1457-61 [15505165.001]
  • [Cites] Ann Neurol. 1981 Feb;9(2):174-81 [7235632.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] Radiology. 1992 Apr;183(1):227-38 [1549677.001]
  • [Cites] Acta Neuropathol. 1995;90(4):387-99 [8546029.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14152-7 [8943076.001]
  • [Cites] J Child Neurol. 1997 Feb;12(2):85-90 [9075016.001]
  • [Cites] Arch Neurol. 1998 Mar;55(3):379-84 [9520012.001]
  • [Cites] Acta Radiol. 1998 Sep;39(5):482-6 [9755694.001]
  • [Cites] Ann Neurol. 1998 Dec;44(6):858-66 [9851429.001]
  • [Cites] J Child Neurol. 2004 Sep;19(9):643-9 [15563009.001]
  • [Cites] J Child Neurol. 2004 Sep;19(9):650-7 [15563010.001]
  • [Cites] J Child Neurol. 2004 Sep;19(9):658-65 [15563011.001]
  • [Cites] Neurology. 2005 Jul 26;65(2):235-8 [16043792.001]
  • [Cites] Pediatr Radiol. 2006 Feb;36(2):119-25 [16283285.001]
  • [Cites] J Child Neurol. 2005 Oct;20(10):837-41 [16417883.001]
  • [Cites] Pediatr Radiol. 2006 Jun;36(6):498-501 [16568295.001]
  • [Cites] Diagn Interv Radiol. 2006 Jun;12(2):57-60 [16752348.001]
  • [Cites] Epilepsia. 2006 Sep;47(9):1543-9 [16981871.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]
  • [Cites] Neurology. 2007 Jan 2;68(1):62-4 [17200495.001]
  • [Cites] Genet Med. 2007 Feb;9(2):88-100 [17304050.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Mar;21(3):557-60 [10730651.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):189-202 [17637444.001]
  • [Cites] Trends Mol Med. 2007 Aug;13(8):319-26 [17632034.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Oct;28(9):1662-7 [17893226.001]
  • [Cites] Epilepsia. 2008;49 Suppl 2:53-62 [18226172.001]
  • [Cites] Neurology. 2008 Mar 18;70(12):916-23 [18032744.001]
  • [Cites] Neurology. 2008 Mar 18;70(12):908-15 [18032745.001]
  • [Cites] Epilepsia. 2009 Jan;50(1):147-54 [19125835.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • (PMID = 20352250.001).
  • [ISSN] 1432-1459
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS024279; None / None / / P01 NS024279-23; United States / NINDS NIH HHS / NS / P01 NS024279-23; Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Other-IDs] NLM/ NIHMS279080; NLM/ PMC3075858
  •  go-up   go-down


41. Rosenfeld A, Listernick R, Charrow J, Goldman S: Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst; 2010 May;26(5):663-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Neurofibromatosis type 1 (NF1), a common genetic disorder, predisposes patients to the development of both benign and malignant tumors.
  • Although the most common central nervous system (CNS) tumor is a low-grade pilocytic astrocytoma of the optic pathway, there have been sporadic reports of NF1 patients with more aggressive CNS lesions.
  • METHODS: We conducted a retrospective review of all patients with NF1 and any CNS tumor being followed in the Children's Memorial Hospital NF1 Clinic.
  • RESULTS: Seven hundred forty patients with a diagnosis of NF1 were identified.
  • The mean age at diagnosis of NF1 was 2 years.
  • Currently, two patients are alive and receiving therapy at a mean of 10 months following diagnosis.
  • [MeSH-major] Brain Neoplasms / complications. Neurofibromatosis 1 / complications

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2002 Sep 10;59(5):759-61 [12221173.001]
  • [Cites] Neurol Clin. 2002 Aug;20(3):841-65 [12432832.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):630-7; discussion 646-51 [12403562.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):925-46, viii [17964021.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):473-8 [9815707.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] Pediatr Neurol. 2005 Apr;32(4):221-8 [15797177.001]
  • [Cites] Neurocirugia (Astur). 2002 Apr;13(2):128-31 [12058604.001]
  • [Cites] Neurology. 1996 Jun;46(6):1652-60 [8649565.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] Leukemia. 1993 Jun;7(6):912-5 [8388972.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1397-400 [14638962.001]
  • (PMID = 19937438.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Rose SR, Danish RK, Kearney NS, Schreiber RE, Lustig RH, Burghen GA, Hudson MM: ACTH deficiency in childhood cancer survivors. Pediatr Blood Cancer; 2005 Nov;45(6):808-13
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACTH deficiency in childhood cancer survivors.
  • We assessed the prevalence of ACTHD in survivors of childhood cancer according to tumor diagnosis/therapy.
  • PROCEDURE: Chart review of endocrine/oncology history was performed in 310 childhood cancer survivors.
  • Of the 56 with ACTHD, 53 (95%) had received cranial irradiation (mean 45.5 Gy, range 14-70 Gy); three had not: one each with craniopharyngioma, hypothalamic astrocytoma, and brain stem glioma.
  • CONCLUSIONS: Childhood cancer survivors with greatest risk for ACTHD had craniopharyngioma, other suprasellar tumor, or medulloblastoma or > or =24 Gy cranial irradiation.
  • We recommend annual testing for ACTHD for 10-15 years and continued lifelong surveillance after CNS tumor or cranial irradiation, in patients with other hypothalamic-pituitary deficiencies or symptoms of ACTHD.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - ACTH Deficiency.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15700255.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


43. Berhouma M: Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. World J Pediatr; 2010 May;6(2):103-10
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tuberous sclerosis complex (TSC), an autosomal dominant genetic disorder, can lead to the development of hamartomas in various organs, including the heart, lungs, kidneys, skin and brain.
  • The data were collected after a bibliography made using PubMed/Medline with these terms: subependymal, subependymal giant cell astrocytoma, subependymal giant cell tumor, and tuberous sclerosis complex.
  • CONCLUSIONS: An earlier diagnosis of SGCT in neurologically asymptomatic children with TSC may allow a precocious surgical removal of the tumor before the installation of increased intracranial pressure signs, an attitude that is being progressively adopted to lessen the morbimortality rate.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Tuberous Sclerosis / complications
  • [MeSH-minor] Algorithms. Child. Humans. Hydrocephalus / etiology. Intracranial Hypertension / etiology. Mutation. Neurosurgical Procedures. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20490765.001).
  • [ISSN] 1867-0687
  • [Journal-full-title] World journal of pediatrics : WJP
  • [ISO-abbreviation] World J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 60
  •  go-up   go-down


44. Balkanov AS, Makarenko MF, Poliakov PIu, Kachkov IA: [Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain]. Zh Vopr Neirokhir Im N N Burdenko; 2005 Jul-Sep;(3):14-16; discussion 16-7
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain].
  • The postoperative use of lomustin, a nitrosourea agent, was investigated for its impact on the efficiency of hyperfractionated radiation therapy performed in patients with glioblastoma and anaplastic astrocytoma of the brain.
  • A total of 35 patients (26 and 9 patients with glioblastoma and anaplastic astrocytoma, respectively) were followed up.
  • Lomustin in combination with hyperfractionated radiation therapy was found to have no effect on the survival of patients with glioblastoma and anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy. Lomustine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485820.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


45. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H: Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol; 2008 Oct;15(10):2887-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
  • We set out to characterize Gliadel-associated morbidity in our 10-year experience with Gliadel wafers for treatment of malignant glioma.
  • METHODS: We retrospectively reviewed records of 1013 patients undergoing craniotomy for resection of malignant brain astrocytoma (World Health Organization grade III/IV disease).
  • RESULTS: A total of 1013 craniotomies were performed for malignant brain astrocytoma.
  • A total of 288 (28%) received Gliadel wafer (250 glioblastoma multiforme (GBM), 38 anaplastic astrocytoma/anaplastic oligodendroglioma (AA/AO), 166 primary resection, 122 revision resection).
  • Patients in Gliadel versus non-Gliadel cohorts had similar incidences of perioperative surgical site infection (2.8% vs. 1.8%, P = .33), cerebrospinal fluid leak (2.8% vs. 1.8%, P = .33), meninigitis (.3% vs. .3%, P = 1.00), incisional wound healing difficulty (.7% vs. .4%, P = .63), symptomatic malignant edema (2.1% vs. 2.3%, P = 1.00), 3-month seizure incidence (14.6% vs. 15.7%, P = .65), deep-vein thrombosis (6.3% vs. 5.2%, P = .53), and pulmonary embolism (PE) (4.9% vs. 3.7%, P = .41).
  • CONCLUSION: In our experience, use of Gliadel wafer was not associated with an increase in perioperative morbidity after surgical treatment of malignant astrocytoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Biocompatible Materials / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Carmustine / therapeutic use. Decanoic Acids / therapeutic use. Neurosurgical Procedures. Polyesters / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636295.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biocompatible Materials; 0 / Decanoic Acids; 0 / Drug Carriers; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


46. Fryssira H, Leventopoulos G, Psoni S, Kitsiou-Tzeli S, Stavrianeas N, Kanavakis E: Tumor development in three patients with Noonan syndrome. Eur J Pediatr; 2008 Sep;167(9):1025-31
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor development in three patients with Noonan syndrome.
  • The diagnosis of Noonan syndrome is essentially clinical, based upon the distinct phenotype and the involvement of the cardiovascular system.
  • Tumor development is a rare manifestation of Noonan syndrome but can be explained by the molecular pathophysiology involved in the disorder.
  • The second patient, a 1-year-old boy, had a low grade pilocytic astrocytoma, the clinical expression of which was persistent headache.
  • The diagnosis of Noonan syndrome was made based on distinct phenotypic findings in three patients who had different types of tumors.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Granular Cell Tumor / complications. Noonan Syndrome / complications. Seminoma / complications. Testicular Neoplasms / complications

  • Genetic Alliance. consumer health - Noonan Syndrome.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dis Child. 1974 Jan;127(1):48-55 [4809794.001]
  • [Cites] Am J Med Genet. 1994 Nov 1;53(2):187-91 [7856646.001]
  • [Cites] Lancet Neurol. 2006 Nov;5(11):937-48 [17052661.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):331-6 [16474405.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):704-8 [12960218.001]
  • [Cites] Blood. 2004 Jul 15;104(2):307-13 [14982869.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9 [12352332.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 May;29(5):341-4 [17483716.001]
  • [Cites] Acta Neuropathol. 1978 Jun 30;42(3):183-90 [209658.001]
  • [Cites] Arch Pediatr Adolesc Med. 1995 Nov;149(11):1280-1 [7581766.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8816-20 [15604238.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):357-60 [7894486.001]
  • [Cites] Ann Dermatol Venereol. 1979 Jun-Jul;106(6-7):609-10 [228583.001]
  • [Cites] J Med Genet. 2007 Oct;44(10):651-6 [17586837.001]
  • [Cites] South Med J. 2001 Apr;94(4):432-4 [11332913.001]
  • [Cites] Am J Hum Genet. 2002 Jun;70(6):1555-63 [11992261.001]
  • [Cites] Arq Neuropsiquiatr. 2006 Mar;64(1):67-71 [16622556.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:936-54 [13893237.001]
  • [Cites] J Pediatr. 2004 Mar;144(3):368-74 [15001945.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):465-8 [11704759.001]
  • [Cites] Clin Dysmorphol. 2000 Oct;9(4):301-2 [11045593.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):70-4 [17143285.001]
  • [Cites] Eur J Med Genet. 2005 Apr-Jun;48(2):81-96 [16053901.001]
  • [Cites] Eur J Hum Genet. 2003 Jan;11(1):85-8 [12529711.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 15;166(2):124-9 [16631468.001]
  • [Cites] Am J Med Genet. 1985 Jul;21(3):477-90 [3927726.001]
  • [Cites] Am J Med Genet A. 2005 Apr 15;134A(2):165-70 [15723289.001]
  • [Cites] Arq Bras Cardiol. 2000 Nov;75(5):409-12 [11080752.001]
  • [Cites] Pathol Oncol Res. 2006;12(3):143-7 [16998593.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jun;45(6):583-91 [16518851.001]
  • [Cites] J Med Genet. 1987 Jan;24(1):9-13 [3543368.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):1007-12 [17603483.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):331-9 [15818625.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):75-9 [17143282.001]
  • [Cites] Neuroimaging Clin N Am. 1999 Nov;9(4):595-613 [10517936.001]
  • [Cites] Am J Med Genet. 1999 Jan 29;82(3):212-4 [10215542.001]
  • [Cites] Eur J Hum Genet. 2003 Feb;11(2):201-6 [12634870.001]
  • [Cites] Pediatrics. 2007 Jun;119(6):e1325-31 [17515436.001]
  • [Cites] Am J Dis Child. 1968 Oct;116(4):373-80 [4386970.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):1013-7 [17603482.001]
  • (PMID = 18057963.001).
  • [ISSN] 1432-1076
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Jayasinghe SN, Irvine S, McEwan JR: Cell electrospinning highly concentrated cellular suspensions containing primary living organisms into cell-bearing threads and scaffolds. Nanomedicine (Lond); 2007 Aug;2(4):555-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In that study, we demonstrated the process with an immortalized human brain astrocytoma (1321N1, European Collection of Cell Cultures) cell line at a cell concentration of 10(6) cells/ml.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17716138.001).
  • [ISSN] 1748-6963
  • [Journal-full-title] Nanomedicine (London, England)
  • [ISO-abbreviation] Nanomedicine (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Iwami K, Arima T, Ooka F, Asai T, Tambara M, Takaoka T: [Bilateral thalamic glioma in an adult: a case report and review of the literature]. No Shinkei Geka; 2009 Mar;37(3):285-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She complained of memory disorder T1-weighted magnetic resonance imaging revealed enlarged bilateral thalami with homogenous isointensity and no contrast enhancement.
  • Histological examination of the biopsy specimen identified diffuse astrocytoma (WHO grade II).
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Thalamus

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306649.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


49. Yamamoto S, Tetsuka K, Sato Y, Endo S: Unsuspected tracheal web inhibits endotracheal intubation: report of a case. J Anesth; 2010 Feb;24(1):132-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 66-year-old woman was scheduled for resection of a recurrent brain astrocytoma.
  • [MeSH-major] Intraoperative Complications. Intubation, Intratracheal. Trachea / pathology. Tracheal Stenosis / diagnosis
  • [MeSH-minor] Aged. Astrocytoma / complications. Astrocytoma / surgery. Brain Neoplasms / complications. Brain Neoplasms / surgery. Bronchoscopy. Female. Humans. Lasers, Gas / therapeutic use. Neoplasm Recurrence, Local / complications. Neoplasm Recurrence, Local / surgery. Reoperation. Video-Assisted Surgery / instrumentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Pulm Med. 2008 Sep 21;8:18 [18803874.001]
  • [Cites] Anesthesiology. 1996 Mar;84(3):686-99 [8659797.001]
  • [Cites] Br J Anaesth. 1997 Sep;79(3):396-7 [9389866.001]
  • [Cites] Thorax. 1991 Feb;46(2):141-2 [2014496.001]
  • [Cites] Eur Respir J. 1999 Apr;13(4):888-93 [10362058.001]
  • [Cites] Pediatr Radiol. 2004 Mar;34(3):256-8 [14586524.001]
  • [Cites] Proc (Bayl Univ Med Cent). 2006 Jul;19(3):224-5 [17252038.001]
  • [Cites] J Cardiothorac Vasc Anesth. 1996 Jun;10(4):519-20 [8776650.001]
  • (PMID = 20052498.001).
  • [ISSN] 1438-8359
  • [Journal-full-title] Journal of anesthesia
  • [ISO-abbreviation] J Anesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Beaty O 3rd, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, Voss S, Ivy SP, Adamson PC: A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2010 Sep;55(3):440-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Subjects, < or =21 years of age at original diagnosis, received oxaliplatin (130 mg/m(2)) intravenously every 21 days.
  • Histologies included: Ewing sarcoma/peripheral PNET, osteosarcoma, rhabdomyosarcoma, neuroblastoma, high and low grade astrocytoma, brain stem glioma, ependymoma, hepatoblastoma and selected rare tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20658614.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10CA98413; United States / NCI NIH HHS / CA / U10CA98543; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  • [Other-IDs] NLM/ NIHMS218622; NLM/ PMC4665115
  •  go-up   go-down


51. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol; 2006 Mar;59(3):490-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the formation of hamartomas in multiple organs.
  • METHODS: Five subjects with clinically definite TSC and either subependymal giant cell astrocytomas (n = 4) or a pilocytic astrocytoma (n = 1) were treated with oral rapamycin at standard immunosuppressive doses (serum levels 5-15 ng/ml) from 2.5 to 20 months.
  • [MeSH-major] Astrocytoma / drug therapy. Astrocytoma / etiology. Brain Neoplasms / drug therapy. Immunosuppressive Agents. Regression (Psychology). Sirolimus / therapeutic use. Tuberous Sclerosis / complications


52. Kumandaş S, Per H, Gümüş H, Tucer B, Yikilmaz A, Kontaş O, Coşkun A, Kurtsoy A: Torticollis secondary to posterior fossa and cervical spinal cord tumors: report of five cases and literature review. Neurosurg Rev; 2006 Oct;29(4):333-8; discussion 338
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired torticollis is not a diagnosis but rather a sign of an underlying disorder.
  • The causes of acquired torticollis include ligamentous, muscular, osseous, ocular, psychiatric, and neurologic disorders and may be a symptom of significant abnormalities of the spinal cord and brain, such as spinal syrinx or central nervous system neoplasia.
  • We report five cases of pediatric tumors with torticollis at the onset: an astrocytoma originating from the medulla oblongata, another presumptive astrocytoma of the spinal cord located between C1 and C6 cervical vertebrae (not operated), an ependymoma located throughout the whole cervical spinal cord extending into the bulbomedullary junction, an astrocytoma originating from the bulbus and extending into the posterior fossa, and another case of a eosinophilic granuloma located extradurally through the anterior and posterior portions of the vertebral bodies from C3 to C7 producing the collapse of the sixth cervical vertebra.
  • All these cases reflect the misinterpretation of this neurological sign and the lack of association with the possibility of spinal or posterior fossa tumor.
  • This delay in the diagnosis of these diseases led to progressive neurological deterioration and to the increase in the tumor size, which made surgical intervention difficult and the prognosis unfavorable.
  • Although torticollis secondary to tumors is rarely seen, it is necessary to be kept in mind in the differential diagnosis.
  • [MeSH-major] Astrocytoma / complications. Eosinophilic Granuloma / complications. Ependymoma / complications. Infratentorial Neoplasms / complications. Spinal Cord Neoplasms / complications. Torticollis / etiology
  • [MeSH-minor] Child. Child, Preschool. Cranial Fossa, Posterior / pathology. Craniotomy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Spinal Cord / pathology. Tomography, X-Ray Computed

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ir Med J. 2001 Feb;94(2):52-3 [11321174.001]
  • [Cites] Mov Disord. 1997 May;12(3):443-7 [9159745.001]
  • [Cites] Spine (Phila Pa 1976). 2002 Jul 1;27(13):1408-13 [12131737.001]
  • [Cites] J Pediatr. 1992 Feb;120(2 Pt 1):266-9 [1735825.001]
  • [Cites] J Neurosurg. 1988 Nov;69(5):772-4 [3183736.001]
  • [Cites] Clin Pediatr (Phila). 1982 Feb;21(2):71-6 [7056009.001]
  • [Cites] Neurology. 1983 Jul;33(7):946-8 [6683382.001]
  • [Cites] Semin Surg Oncol. 1999 Mar;16(2):73-90 [9988865.001]
  • [Cites] Neurology. 1983 Sep;33(9):1237-40 [6684264.001]
  • [Cites] Neuroscience. 1999;93(3):1095-107 [10473274.001]
  • [Cites] J Manipulative Physiol Ther. 1994 Feb;17 (2):113-8 [8169539.001]
  • [Cites] J Bone Joint Surg Am. 1965 Mar;47:223-48 [14261800.001]
  • [Cites] Rev Neurol. 2001 Jan 1-15;32(1):60-2 [11293103.001]
  • [Cites] Mov Disord. 1994 Sep;9(5):493-507 [7990845.001]
  • [Cites] AMA J Dis Child. 1959 Dec;98:756-64 [14411090.001]
  • [Cites] Mov Disord. 2003 Jan;18(1):60-9 [12518301.001]
  • [Cites] Spine (Phila Pa 1976). 2001 May 15;26(10 ):1193-6 [11413437.001]
  • [Cites] J Neurophysiol. 1999 Jul;82(1):34-41 [10400932.001]
  • [Cites] Brain. 1985 Jun;108 ( Pt 2):463-83 [4005532.001]
  • [Cites] Orthop Rev. 1991 Aug;20(8):667-74 [1923581.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1036-43 [8929492.001]
  • [Cites] Postgrad Med. 1984 May 15;75(7):126-34 [6718288.001]
  • [Cites] Childs Nerv Syst. 1995 Feb;11(2):86-8 [7758017.001]
  • [Cites] J Neurosurg Sci. 1981 Jul-Dec;25(3-4):259-64 [7346619.001]
  • [Cites] Bol Asoc Med P R. 1984 Feb;76(2):62-5 [6584113.001]
  • [Cites] Br J Psychiatry. 1979 Mar;134:306-7 [509012.001]
  • [Cites] Ned Tijdschr Geneeskd. 1998 Jul 4;142(27):1573-4 [9763834.001]
  • [Cites] Mov Disord. 1995 Jul;10(4):500-3 [7565833.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1990 Jul-Aug;27(4):202-4 [2391622.001]
  • [Cites] Plast Reconstr Surg. 1965 Jan;35:14-25 [14231376.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1996 Jun;36(1):39-44 [8803690.001]
  • [Cites] J Pediatr Orthop. 1996 Jul-Aug;16(4):505-7 [8784707.001]
  • [Cites] Adv Neurol. 1988;50:501-8 [3400505.001]
  • (PMID = 16924460.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A, Mokbel K, Mansel RE: Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer; 2005 Jul;41(11):1628-36
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes.
  • PURPOSE: The tuberous sclerosis (TSC) genes TSC1 and TSC2 encode the protein products hamartin and tuberin, respectively, and are putative tumour suppressor genes.
  • Germ-line mutation of either TSC gene leads to the development of the heritable disorder TSC.
  • This disorder is characterized by the development of hamartomas in many organs and is associated with the proliferative lung disease, lymphangioleiomyomatosis, the brain tumour giant cell astrocytoma and occasionally with renal cell carcinoma.
  • However, the TSC genes have not been studied in breast cancer.
  • The current study investigated the expression of the TSC gene products and the potential mechanisms of their aberrancy in human breast cancer cells and tissues.
  • In invasive tumour tissues, however, the staining of both proteins were to be markedly reduced (P < 0.01).
  • At message level, although normal and tumour tissues expressed both TSC products, the transcript levels of tuberin was significantly lower in tumour tissues compared with normal tissues (P < 0.05).
  • Tumours from patients who developed recurrence and died from breast cancer had significantly low levels of tuberin compared with those who remained disease free (P = 0.03 and 0.05, respectively).
  • CONCLUSION: TSC1 genes are aberrantly expressed in human breast cancer cell lines and breast tumour tissues and their promoters are seen to be methylated in breast tumour tissues.
  • The expression of TSC1 is associated with an unfavourable clinical outcome in patients with breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Repressor Proteins / genetics. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Immunohistochemistry. Methylation. Promoter Regions, Genetic. Recurrence

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951164.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  •  go-up   go-down


54. Sherwood PR, Donovan HS, Given CW, Lu X, Given BA, Hricik A, Bradley S: Predictors of employment and lost hours from work in cancer caregivers. Psychooncology; 2008 Jun;17(6):598-605
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of employment and lost hours from work in cancer caregivers.
  • Family caregivers (N=80) of persons with a primary malignant brain tumor participated in a 45-60 min telephone interview, answering questions regarding the impact of providing care on their emotional health and employment status.
  • Caregivers were more likely to report lost hours from work when care recipients required assistance with Instrumental Activities of Daily Living (IADLs) and were closer to the time of diagnosis.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Caregivers.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957756.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] ENG
  • [Grant] United States / NINR NIH HHS / NR / F31 NR008069; United States / NINR NIH HHS / NR / F31NR8069
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS779536; NLM/ PMC4846278
  •  go-up   go-down


55. Ambrosini E, Serafini B, Lanciotti A, Tosini F, Scialpi F, Psaila R, Raggi C, Di Girolamo F, Petrucci TC, Aloisi F: Biochemical characterization of MLC1 protein in astrocytes and its association with the dystrophin-glycoprotein complex. Mol Cell Neurosci; 2008 Mar;37(3):480-93
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MLC1 gene mutations have been associated with megalencephalic leukoencephalopathy with subcortical cysts (MLC), a rare neurologic disorder in children.
  • Using a newly developed anti-human MLC1 polyclonal antibody, we have investigated the biochemical properties and localization of MLC1 in cultured astrocytes and brain tissue and searched for evidence of a relationship between MLC1 and proteins of the dystrophin-glycoprotein complex (DGC).
  • Most importantly, we show that the membrane-associated component of MLC1 (60-64 kDa) localizes in astrocytic lipid rafts together with dystroglycan, syntrophin and caveolin-1, and co-fractionates with the DGC in whole rat brain tissue.
  • In the human brain, MLC1 protein is expressed in astrocyte processes and ependymal cells, where it colocalizes with dystroglycan and syntrophin.
  • [MeSH-major] Astrocytes / metabolism. Dystroglycans / metabolism. Neoplasm Proteins / chemistry. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / chemistry. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Animals. Animals, Newborn. Astrocytoma / pathology. Brain / cytology. Cells, Cultured. Dystrophin-Associated Proteins / metabolism. Humans. Membrane Microdomains / metabolism. Myeloid Cell Leukemia Sequence 1 Protein. RNA, Messenger / metabolism. Rats. Subcellular Fractions / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165104.001).
  • [ISSN] 1095-9327
  • [Journal-full-title] Molecular and cellular neurosciences
  • [ISO-abbreviation] Mol. Cell. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dystrophin-Associated Proteins; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / syntrophin; 146888-27-9 / Dystroglycans
  •  go-up   go-down


56. Tian R, Gregor M, Wiche G, Goldman JE: Plectin regulates the organization of glial fibrillary acidic protein in Alexander disease. Am J Pathol; 2006 Mar;168(3):888-97
Genetic Alliance. consumer health - Alexander Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alexander disease (AxD) is a rare but fatal neurological disorder caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP).
  • Here, we describe the expression of the cytoskeletal linker protein plectin in the AxD brain.
  • RFs displayed positive immunostaining for plectin and GFAP, both of which were increased in the AxD brain.
  • Compared to wild-type GFAP expression, RC GFAP expression lowered plectin levels in astrocytoma-derived stable transfectants and plectin-positive fibroblasts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1998 Nov 1;12(21):3442-51 [9808630.001]
  • [Cites] Acta Neuropathol. 1998 Sep;96(3):215-21 [9754951.001]
  • [Cites] Biol Chem. 1999 Feb;380(2):151-8 [10195422.001]
  • [Cites] C R Biol. 2004 Nov;327(11):970-6 [15628219.001]
  • [Cites] J Cell Sci. 2005 May 1;118(Pt 9):2057-65 [15840648.001]
  • [Cites] J Cell Sci. 2000 Feb;113 ( Pt 3):483-91 [10639335.001]
  • [Cites] Neuroreport. 2000 Feb 7;11(2):361-5 [10674487.001]
  • [Cites] Brain Res. 2000 Feb 28;857(1-2):291-4 [10700580.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5665-79 [10891503.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):117-20 [11138011.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):563-73 [11398833.001]
  • [Cites] Am J Hum Genet. 2001 Nov;69(5):1134-40 [11567214.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jun;61(6):520-30 [12071635.001]
  • [Cites] J Neurovirol. 2003 Jun;9(3):372-89 [12775420.001]
  • [Cites] Nat Med. 2004 Jul;10 Suppl:S2-9 [15272266.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1982;46 Pt 1:475-82 [6955088.001]
  • [Cites] J Biol Chem. 1987 Jan 25;262(3):1320-5 [3027087.001]
  • [Cites] Am J Pathol. 1988 Mar;130(3):569-78 [3348359.001]
  • [Cites] J Pediatr. 1989 Jan;114(1):104-7 [2909695.001]
  • [Cites] Eur Neurol. 1993;33(6):454-60 [8307068.001]
  • [Cites] J Cell Biol. 1996 Sep;134(6):1455-67 [8830774.001]
  • [Cites] Mol Biol Rep. 1996;23(1):35-46 [8983017.001]
  • [Cites] Genes Dev. 1997 Dec 1;11(23):3143-56 [9389647.001]
  • [Cites] J Cell Sci. 1998 Sep;111 ( Pt 17):2477-86 [9701547.001]
  • [Cites] J Neurocytol. 1998 Jun;27(6):431-40 [10192524.001]
  • (PMID = 16507904.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS042803; United States / NINDS NIH HHS / NS / NS42803
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Plectin
  • [Other-IDs] NLM/ PMC1606531
  •  go-up   go-down


57. Bachetti T, Di Zanni E, Balbi P, Bocca P, Prigione I, Deiana GA, Rezzani A, Ceccherini I, Sechi G: In vitro treatments with ceftriaxone promote elimination of mutant glial fibrillary acidic protein and transcription down-regulation. Exp Cell Res; 2010 Aug 1;316(13):2152-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alexander disease is a rare, untreatable and usually fatal neurodegenerative disorder caused by heterozygous mutations of the glial fibrillary acidic protein (GFAP) gene which ultimately lead to formation of aggregates, containing also alphaB-Crystallin, HSP27, ubiquitin and proteasome components.
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / metabolism. Autophagy. Blotting, Western. Brain Neoplasms / drug therapy. Brain Neoplasms / metabolism. Cell Proliferation. Fluorescent Antibody Technique. Humans. In Vitro Techniques. Luciferases / metabolism. Mutant Proteins / genetics. Mutant Proteins / metabolism. Promoter Regions, Genetic / genetics. Proteasome Endopeptidase Complex / drug effects. Protein Multimerization. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism. Ubiquitin / metabolism

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471977.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Glial Fibrillary Acidic Protein; 0 / HSP27 Heat-Shock Proteins; 0 / Mutant Proteins; 0 / RNA, Messenger; 0 / Ubiquitin; 0 / alpha-Crystallin B Chain; 75J73V1629 / Ceftriaxone; EC 1.13.12.- / Luciferases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


58. Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M: The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer; 2009 May 15;115(10):2031-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular growth factor concentration raises because of increased levels of MIF in brain tumors.
  • Recently, the MIF receptor complex has been described, and it appears that this may be a suitable drug target for treatment of brain tumors.
  • In light of these findings, the authors chose to conduct a systematic search for information regarding MIF that has been published within the past 15 years using the terms "inflammation," "glioblastoma," "brain tumor," "astrocytoma," "microglia," "glioblastoma," "immune system and brain tumors," "glioblastoma and MIF," and "brain tumor and MIF."
  • The aim of this article was thus to present a detailed review of current knowledge regarding the role of MIF in CNS tumor pathophysiology.
  • [MeSH-minor] Brain Neoplasms / metabolism. Cell Transformation, Neoplastic. Drug Delivery Systems. Humans. Neovascularization, Pathologic / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19326434.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Macrophage Migration-Inhibitory Factors
  • [Number-of-references] 67
  •  go-up   go-down


59. Xiang YY, Dong H, Wan Y, Li J, Yee A, Yang BB, Lu WY: Versican G3 domain regulates neurite growth and synaptic transmission of hippocampal neurons by activation of epidermal growth factor receptor. J Biol Chem; 2006 Jul 14;281(28):19358-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Versican is one of the major extracellular matrix (ECM) proteins in the brain.
  • Recent findings have revealed that peptide fragments containing the versican C terminus (G3 domain) are present in human brain astrocytoma.
  • [MeSH-major] Brain Neoplasms / metabolism. Chondroitin Sulfate Proteoglycans / physiology. Hippocampus / metabolism. Lectins, C-Type / physiology. Neurons / metabolism. Receptor, Epidermal Growth Factor / metabolism. Synaptic Transmission
  • [MeSH-minor] Animals. Astrocytoma / metabolism. Brain / metabolism. Brain / pathology. Cell Line, Tumor. Extracellular Matrix / metabolism. Humans. Protein Structure, Tertiary. Rats. Versicans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648628.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chondroitin Sulfate Proteoglycans; 0 / Cspg2 protein, rat; 0 / Lectins, C-Type; 0 / VCAN protein, human; 126968-45-4 / Versicans; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


60. Jozwiak J, Kotulska K, Grajkowska W, Jozwiak S, Zalewski W, Oldak M, Lojek M, Rainko K, Maksym R, Lazarczyk M, Skopinski P, Wlodarski P: Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. Brain Dev; 2007 Jun;29(5):273-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis (TS), autosomal dominant disorder manifested by the formation of usually benign tumors in the brain, heart, kidneys and skin, results from an inactivating mutation in one of two tumor suppressor genes TSC1 or TSC2.
  • In order to test this hypothesis we evaluated samples of four subependymal giant cell astrocytomas (SEGAs), brain tumors developing in the progress of TS.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / physiopathology. Brain Neoplasms / complications. Brain Neoplasms / physiopathology. Signal Transduction / physiology. Tuberous Sclerosis / etiology. Tuberous Sclerosis / physiopathology. Up-Regulation / physiology. Wnt Proteins / physiology


61. Kyprianou N, Murphy E, Lee P, Hargreaves I: Assessment of mitochondrial respiratory chain function in hyperphenylalaninaemia. J Inherit Metab Dis; 2009 Apr;32(2):289-96
Hazardous Substances Data Bank. (L)-Phenylalanine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phenylketonuria (PKU) is an autosomal recessive disorder resulting in neurological and intellectual disability when untreated.
  • It has been suggested that the hyperphenylalaninaemia in patients with PKU reduces complex I (NADH:ubiquinone reductase) activity of the mitochondrial respiratory chain (MRC) and/or biosynthesis of coenzyme Q(10) (CoQ(10)), which acts as an electron carrier in the MRC, leading to impaired energy metabolism in the brain of patients with PKU and hence the neurological pathology.
  • Human 1321N1 astrocytoma cells were exposed to hyperphenylalaninaemia by the addition of 300 or 900 micromol/L of Phe to the cell culture medium.
  • [MeSH-minor] Adult. Cell Line, Tumor. Cells, Cultured. Culture Media. Female. Humans. Lactic Acid / metabolism. Male. Middle Aged. Phenylketonurias / blood. Phenylketonurias / metabolism. Pyruvic Acid / metabolism. Tremor / blood. Tremor / etiology. Tyrosine / blood. Ubiquinone / analogs & derivatives. Ubiquinone / blood. Young Adult

  • MedlinePlus Health Information. consumer health - Amino Acid Metabolism Disorders.
  • MedlinePlus Health Information. consumer health - Mitochondrial Diseases.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277893.001).
  • [ISSN] 1573-2665
  • [Journal-full-title] Journal of inherited metabolic disease
  • [ISO-abbreviation] J. Inherit. Metab. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Culture Media; 1339-63-5 / Ubiquinone; 33X04XA5AT / Lactic Acid; 42HK56048U / Tyrosine; 47E5O17Y3R / Phenylalanine; 8558G7RUTR / Pyruvic Acid; EJ27X76M46 / coenzyme Q10
  •  go-up   go-down


62. Fernø J, Skrede S, Vik-Mo AO, Håvik B, Steen VM: Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci; 2006;7:69
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The etiology of schizophrenia is unknown, but neurodevelopmental disturbances, myelin- and oligodendrocyte abnormalities and synaptic dysfunction have been suggested as pathophysiological factors in this severe psychiatric disorder.
  • Glial-like cells (GaMg glioma and CCF-STTG1 astrocytoma cell lines) displayed more pronounced drug-induced SREBP activation compared to the response in HCN2 human cortical neurons and SH-SY5Y neuroblastoma cells, indicating that antipsychotic-induced activation of lipogenesis is most prominent in glial cells.
  • [MeSH-minor] Cell Line, Tumor. Dose-Response Relationship, Drug. Gene Expression Profiling. Humans

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10647-52 [12963821.001]
  • [Cites] Neurosci Lett. 2006 Mar 13;395(3):185-90 [16324787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-32 [14512514.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1738-49 [14585943.001]
  • [Cites] J Lipid Res. 2004 Aug;45(8):1375-97 [15254070.001]
  • [Cites] Anticancer Res. 1988 Jul-Aug;8(4):797-803 [3178168.001]
  • [Cites] Am J Med Genet. 1994 May 1;50(4):355-7 [8209915.001]
  • [Cites] J Biol Chem. 1994 Nov 25;269(47):29371-4 [7961912.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1575-84 [8833906.001]
  • [Cites] J Clin Invest. 1997 Mar 1;99(5):838-45 [9062340.001]
  • [Cites] J Clin Invest. 1997 Mar 1;99(5):846-54 [9062341.001]
  • [Cites] Neuropsychopharmacology. 1997 Jun;16(6):385-98 [9165494.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):5987-92 [9600904.001]
  • [Cites] Am J Psychiatry. 1998 Jun;155(6):751-60 [9619146.001]
  • [Cites] Eur Neuropsychopharmacol. 1999 Mar;9(3):253-6 [10208296.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Am J Psychiatry. 1999 Jun;156(6):885-90 [10360127.001]
  • [Cites] Neuroscience. 1999;91(4):1247-55 [10391432.001]
  • [Cites] Am J Psychiatry. 1999 Nov;156(11):1686-96 [10553730.001]
  • [Cites] J Lipid Res. 1999 Dec;40(12):2264-70 [10588952.001]
  • [Cites] Arch Gen Psychiatry. 2000 Jan;57(1):65-73 [10632234.001]
  • [Cites] Psychopharmacology (Berl). 2000 Jan;148(1):3-15 [10663410.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4746-51 [11296301.001]
  • [Cites] Trends Neurosci. 2001 Aug;24(8):479-86 [11476888.001]
  • [Cites] Brain Res Bull. 2001 Jul 15;55(5):597-610 [11576756.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1354-7 [11701931.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45408-16 [11577112.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1125-31 [11994399.001]
  • [Cites] Bioessays. 2003 Jan;25(1):72-8 [12508285.001]
  • [Cites] Neuropsychopharmacology. 2003 Mar;28(3):519-26 [12629531.001]
  • [Cites] Arch Gen Psychiatry. 2003 May;60(5):443-56 [12742865.001]
  • [Cites] Arch Gen Psychiatry. 2003 Jun;60(6):553-64 [12796218.001]
  • [Cites] Biol Psychiatry. 2003 Jun 15;53(12):1075-85 [12814859.001]
  • [Cites] J Psychiatry Neurosci. 2003 Jul;28(4):275-84 [12921222.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11235-40 [10500160.001]
  • [Cites] Pharmacopsychiatry. 2004 Nov;37(6):243-65 [15551191.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52772-80 [15452130.001]
  • [Cites] Mol Psychiatry. 2005 Jan;10(1):79-104 [15289815.001]
  • [Cites] Nat Neurosci. 2005 Apr;8(4):468-75 [15793579.001]
  • [Cites] Mol Cell Neurosci. 2005 Jun;29(2):190-201 [15911344.001]
  • [Cites] Pharmacogenomics J. 2005;5(5):298-304 [16027736.001]
  • [Cites] Lancet. 2003 Sep 6;362(9386):798-805 [13678875.001]
  • (PMID = 17052361.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Sterol Regulatory Element Binding Proteins
  • [Other-IDs] NLM/ PMC1635424
  •  go-up   go-down


63. Vik-Mo AO, Fernø J, Skrede S, Steen VM: Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol; 2009;9:10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Disturbances in lipid homeostasis and myelination have been proposed in the pathophysiology of schizophrenia and bipolar disorder.
  • The effect of some of these drugs was also investigated in human astrocytoma (CCF-STTG1), neuroblastoma (SH-SY5Y) and hepatocellular carcinoma (HepG2) cells.
  • [MeSH-major] Apolipoprotein E2 / genetics. Brain / drug effects. Cholesterol / metabolism. Liver / drug effects. Psychotropic Drugs / pharmacology. Up-Regulation
  • [MeSH-minor] ATP-Binding Cassette Transporters / genetics. ATP-Binding Cassette Transporters / metabolism. Analysis of Variance. Blotting, Western. Cell Line, Tumor. Dose-Response Relationship, Drug. Humans. Hydroxymethylglutaryl CoA Reductases / genetics. Hydroxymethylglutaryl CoA Reductases / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sterol Regulatory Element Binding Proteins. Time Factors

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Psychiatry. 2010 May;15(5):463-72 [18936756.001]
  • [Cites] Mol Psychiatry. 2009 Mar;14(3):308-17 [18195716.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4746-51 [11296301.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1354-7 [11701931.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1243-8 [12411951.001]
  • [Cites] J Physiol Paris. 2002 Apr-Jun;96(3-4):257-63 [12445904.001]
  • [Cites] Biol Psychiatry. 2003 Sep 15;54(6):616-22 [13129656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10647-52 [12963821.001]
  • [Cites] Lancet. 2003 Sep 6;362(9386):758 [13678867.001]
  • [Cites] Lancet. 2003 Sep 6;362(9386):798-805 [13678875.001]
  • [Cites] Diabetes Care. 2004 Feb;27(2):596-601 [14747245.001]
  • [Cites] Science. 2004 Feb 20;303(5661):1201-4 [14976318.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1168-75 [15085196.001]
  • [Cites] J Lipid Res. 2004 Aug;45(8):1375-97 [15254070.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48801-7 [15358760.001]
  • [Cites] Biol Psychiatry. 2005 Apr 1;57(7):711-5 [15820227.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):59-63 [15913974.001]
  • [Cites] Pharmacogenomics J. 2005;5(5):298-304 [16027736.001]
  • [Cites] Schizophr Res. 2005 Dec 1;80(1):55-9 [15964176.001]
  • [Cites] Neurosci Lett. 2006 Mar 13;395(3):185-90 [16324787.001]
  • [Cites] J Mol Med (Berl). 2006 Apr;84(4):266-75 [16328207.001]
  • [Cites] Biochem Soc Trans. 2006 Jun;34(Pt 3):399-403 [16709172.001]
  • [Cites] Am J Psychiatry. 2006 Jul;163(7):1276-9 [16816235.001]
  • [Cites] CNS Spectr. 2006 Jul;11(7 Suppl 7):32-9 [16816798.001]
  • [Cites] Mol Cell Biochem. 2006 Sep;289(1-2):167-73 [16718372.001]
  • [Cites] BMC Neurosci. 2006;7:69 [17052361.001]
  • [Cites] Neuropsychopharmacology. 2007 Apr;32(4):765-72 [16823387.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2007 Jun;6(3):219-33 [17511618.001]
  • [Cites] Mol Psychiatry. 2007 Jun;12(6):562-71 [17211438.001]
  • [Cites] Schizophr Res. 2007 Jul;93(1-3):13-22 [17407804.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):21090-9 [17526932.001]
  • [Cites] Pharmacol Res. 2007 Sep;56(3):202-8 [17651982.001]
  • [Cites] J Psychiatry Neurosci. 2007 Sep;32(5):331-8 [17823649.001]
  • [Cites] J Neurosci. 2007 Dec 26;27(52):14470-80 [18160655.001]
  • [Cites] Int J Neuropsychopharmacol. 2008 Feb;11(1):49-61 [17708778.001]
  • [Cites] Psychiatry Res. 2008 Feb 28;158(1):75-8 [18096247.001]
  • [Cites] Mol Psychiatry. 2008 Jul;13(7):697-708 [17684494.001]
  • [Cites] Hippocampus. 2008;18(7):631-9 [18306301.001]
  • [Cites] Int J Neuropsychopharmacol. 2008 Aug;11(5):679-84 [18241359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4066-71 [11274430.001]
  • (PMID = 19715613.001).
  • [ISSN] 1471-2210
  • [Journal-full-title] BMC pharmacology
  • [ISO-abbreviation] BMC Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apolipoprotein E2; 0 / Psychotropic Drugs; 0 / Sterol Regulatory Element Binding Proteins; 97C5T2UQ7J / Cholesterol; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases
  • [Other-IDs] NLM/ PMC2753324
  •  go-up   go-down






Advertisement